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Abstract 
A structure-based virtual screening technique was applied to the study of the HCV NS3 helicase, with 
the aim to find novel inhibitors of the HCV replication. A library of ~450000 commercially available 
compounds was analysed in silico and 21 structures were selected for biological evaluation in the HCV 
replicon assay. One hit characterised by a substituted thieno-pyrimidine scaffold was found to inhibit the 
viral replication with an EC50 value in the sub-micromolar range and a good selectivity index. Different 
series of novel thieno-pyrimidine derivatives were designed and synthesised; several new structures 
showed antiviral activity in the low or sub-micromolar range. 
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1. Introduction 
Hepatitis C virus (HCV) is one of the first causes of chronic liver disease and it currently affects 130-
150 million people worldwide [1]. The infection becomes chronic in 60-85% of patients and leads to the 
development of hepatic steatosis, fibrosis, cirrhosis and hepatocellular carcinoma [2, 3]. A vaccine 
against this virus is still not available, while the standard of care was for long a combination of pegylated 
interferon (pegIFN) and ribavirin, a therapy not specific for HCV and efficient in 50% of treated patients, 
with many associated side effects [4]. HCV single-stranded, positive-sense, 9.6 kb RNA genome encodes 
six non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B), all essential for the viral 
replication [5]. In the last decade great progress has been made in the development of safe and highly 
potent inhibitors of HCV replication targeting the NS3 protease [6, 7], the NS5B polymerase [8], the 
NS4B protein [9] and the NS5A protein [10].  Even if all-oral treatment regimens of chronically infected 
patients with a combination therapy of either viral NS5B polymerase, NS3 protease or NS5A inhibitors 
are showing promising results, these treatments are associated with high costs [11, 12], while resistant 
viral strains have been reported for each clinically approved direct-acting antiviral [13-17]. These 
                                                        
1
 Corresponding author 
E-mail address: bassettom@cardiff.ac.uk (Dr. M. Bassetto) 
 
 2 
limitations highlight the need for new therapeutics that will reduce the costs of treatment and avoid the 
development of resistance. 
Despite the abundance of structural and mechanistic information on the HCV NS3 helicase [18], this 
enzyme is still underexploited, with very few inhibitors reported so far, none of which taken into clinical 
development [19]. The protein main function, essential for the viral replication [20, 21], is the unwinding 
of double-stranded RNA sequences, formed as an intermediate of the viral nucleic acid synthesis; this 
process is permitted by ATP hydrolysis [22, 23]. 
Due to the essential role of a functional NS3 helicase for HCV replication, this enzyme was chosen as 
target for the computer-aided identification and synthesis of viral replication inhibitors. The SPECS 
library of commercially available small molecules [24] was screened in silico on the enzyme known 
RNA binding cleft, leading to the selection of 21 compounds that were analysed in the HCV replicon 
assay. A first hit was found to inhibit the viral replication with an EC50 in the sub-micromolar range and 
a good selectivity index. Its thieno-pyrimidine scaffold was the starting point for the design and synthesis 
of different series of new analogues, with which the main chemical features were explored. Several new 
derivatives were found to inhibit the HCV replication with EC50 values in the low or sub-micromolar 
range. 
 
2 Results and discussion 
 
2.1 Structure-based virtual screening 
The HCV NS3 helicase is formed by three domains and occupies the C-terminal portion of the NS3 
protein. It presents multiple ligand-binding regions, the main ones being an ATP binding site in the cleft 
separating domain 1 from domain 2 and a single-stranded nucleic acid binding site at the interface of the 
three domains [25]. The potential interference with the known nucleic acid binding cleft was evaluated 
to screen the SPECS library of commercially available compounds [24]. The 3KQH crystal structure, 
which corresponds to the enzyme high-affinity open conformation bound to a single-stranded DNA 
substrate [26], was used for all the analyses performed. The area defined by Glu493, Asn556 and Phe557 
was chosen as centre for the creation of a pharmacophoric filter, and the residues essential for the helicase 
unwinding activity (Thr269, Arg393, Thr411, Glu493 and Trp501) [27] were considered to build the 
pharmacophore using MOE 2014.10 (Figure 1) [28]. 
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Figure 1: Pharmacophoric model based on the 3KQH crystal structure. The model consists of a polar interaction with either Glu493 
(yellow) or Asn556 (purple), a hydrophobic contact with Trp501 (green), and two hydrogen bond acceptors pointing to Arg393 
(light blue) and Thr411 (orange). Exclusion volumes are hidden for clarity. 
 
Among the approximately 450000 structures in the SPECS database, which were analysed with MOE 
2014.10 conformational search tool prior to filtration [28], 3000 hits were found to match the 
pharmacophoric query. Molecular docking of these compounds in the 3KQH nucleic acid binding cleft 
was performed using Glide in the standard precision SP mode [29]. The output poses were re-scored with 
Glide XP [30], Plants ChemPLP [31] and FlexX [32] scoring functions, and the scoring results were 
combined using a previously reported consensus scoring procedure [33]. 21 derivatives were finally 
selected after visual inspection, purchased and tested in the HCV replicon assay (Table S1). Compound 
1a (Figure 2) showed a promising antiviral effect against HCV replication, with an estimated EC50 <1 
µM and a good selectivity index >141 (Table 1). 
 
Figure 2: Structure and predicted binding mode for compound 1a. 
 
The predicted binding mode found for this structure suggests a good spatial occupation of the target site 
of the HCV NS3 helicase, with the cyclohexyl portion of the molecule in close proximity to Trp501, the 
pyrimidine ring filling the space defined by Glu493 and Asn556, and the opportunity of hydrogen-bond 
formation between the 2’-hydroxyphenyl group and Arg393 lateral chain. Interestingly, 1a shows 
significant structural similarities with a series of previously published HCV NS3 inhibitors, QU663 
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(Figure 3) and its derivatives [34]. Furthermore, the predicted binding mode suggested for these 
structures involves the same sub-pocket of the enzyme nucleic acid binding cleft chosen as target in this 
study. 
 
Figure 3: Chemical structure of potent HCV NS3 helicase inhibitor QU663. 
 
After the structure of 1a was re-synthesised and its potential to inhibit the HCV replication was confirmed 
(Table 1), starting from its scaffold different series of novel thieno-pyrimidine derivatives were 
designed, synthesised and evaluated. 
 
2.2 Chemistry 
The structure of 1a is characterized by a central thieno-pyrimidinic nucleus, condensed with a 
tetrahydrobenzene system at positions 4 and 5 of the thiophene ring, and functionalised with a 2,5-
dihydroxyphenyl-ethylidene moiety via a hydrazone linker at position 4 of the pyrimidine ring. Several 
new derivatives were designed in order to explore the role of the aromatic substituents, the hydrazine 
linker and the cyclic aliphatic moiety on the thiophene portion. 
A first series of differently substituted thieno[2,3-d]pyrimidin-4-yl)-hydrazones was synthesised 
according to an optimised five-step synthetic pathway, developed from previously reported procedures 
(Scheme 1) [35-38]. 
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Scheme 1: Reagents and conditions: (i) Et3N, EtOH, reflux, 24 h (5a-e) or Et3N, DMF, 45 °C, 1 h (5f); (ii) 10% Pd/C, PhMe, 
reflux, 5 d;  (iii) formamide, reflux, 6 h (6a-g from 5a-g) or MeCN, HCl, 1,4-dioxane, r.t., 4 h, 100°C, 16 h (6h from 5a); (iv) N-
Chlorosuccinimmide, AcOH, 95 °C, 1.5 h; (v) POCl3, reflux, 6 h; (vi) hydrazine monohydrate, MeOH, reflux, 8 h; (vii) substituted 
acetophenone or benzaldehyde, EtOH, reflux, 24 h. 
 
The general strategy started with the preparation of 2-amino-thienophene-3-carboxylic acid ethyl esters 
5a-f through a Gewald reaction, which involves the condensation of a ketone or aldehyde with an -
cyanoester in the presence of elemental sulphur and a base. By treating compounds 5a-g with an excess 
of formamide, cyclic pyrimidinones 6a-g were obtained in good yield after crystallisation. Pyrimidinones 
6a-i were chlorinated using phosphorus oxychloride to give intermediate 4-chloro-pyrimidines 7a-d, f-i. 
Aromatic nucleophilic displacement of the chloride leaving group with aqueous hydrazine was then 
carried out to form aromatic hydrazine derivatives 8a-d, f-i, which were finally used for the formation 
of Schiff bases with differently substituted aromatic ketones and aldehydes, giving the final compounds 
1, 9-24. With the purpose to better understand the role of the tetrahydrobenzene substituent on the 
thiophene ring of 1a, along with its replacement with different aliphatic functionalities, the aromatisation 
of this group was planned and carried out. Saturated intermediate 5a was converted into its oxidised 
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analogue 5g by treatment with 10% Pd/C in toluene for 5 days [39]. As a means to explore the role of 
the aromatic proton in the pyrimidine ring, its replacement with a methyl group was designed and 
achieved by condensing aminoester intermediate 5a with acetonitrile instead of formamide. The reaction 
was performed in a saturated HCl solution in dioxane, under pressure in a sealed tube [40]. The mixture 
was sonicated in an ultrasonic bath for 4 h in order to solubilise the starting material, then heated at 100 
°C for 16 h to obtain pyrimidinone 6h with a methyl group replacing the aromatic proton, after 
precipitation by the addition of water. With the aim to insert a chlorine substituent at position 6 of the 
thiophene ring, pyrimidinone 6e was treated with N-chlorosuccinimide in glacial acetic acid for 1.5 h 
under reflux conditions, giving the desired chlorinated product 6i, which was isolated after precipitation 
from water in good yield [41].  
Synthetic efforts were also directed to the replacement of the hydrazone linker in the original active 
scaffold (Scheme 2). In particular, three different chemical functionalities were explored, by the 
substitution of this bond with a hydrazide, sulfonylhydrazine and amino group, respectively. 
 
 
Scheme 2: Reagents and conditions: (i) 2-Pyridine-sulfonyl chloride, Pyridine, 0 °C, 1 h, r.t., 24h; (ii) Aromatic carboxylic acid, 
TBTU, DiPEA, THF, r.t., 5 h; (iii) Aryl-amine, NaHCO3, iPrOH, reflux, 96 h. 
 
Compounds 25-36, with a hydrazide linker that confers higher stability in aqueous systems while 
maintaining the same length of the hydrazone substituent, were obtained through a coupling reaction 
between hydrazine intermediates 8a-i and aromatic carboxylic acids, using TBTU as coupling agent, 
stirring the reaction mixture at r.t. in THF in the presence of DIPEA. Compound 37, with a sulfonyl 
hydrazide linker replacing the original hydrazone group, was obtained by reacting intermediate 8a with 
2-pyridinesulfonyl chloride, stirring the two starting materials in pyridine at 0 °C for 1 h and then at r.t. 
for 24 h. 
Finally, a small series of three amino compounds, 38-40, was obtained by aromatic nucleophilic 
displacement of the chloride leaving group in intermediate 7a with different aromatic amines, refluxing 
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the reaction mixture in iPr-OH for 96 h in the presence of NaHCO3. In this last series of structures, the 
original three-atom linker is shortened and the substituted phenyl ring is replaced with a condensed 
bicyclic aromatic moiety. This significant modification on the original structure was designed after a 
series of conformational analysis studies performed on the structure of 11a, as discussed in paragraph 
2.3. All newly  
 
2.3 Conformational analysis 
In order to understand the role of the 2’-hydroxy group of the hit scaffold, which seems to play a key 
role for the antiviral activity of the new compounds (Table 1), the Conformational Search tool in 
MOE2014.10 was used to analyse the conformational space of 11a in vacuum [28]. An internal hydrogen 
bond between the 2’-hydroxy group and the nitrogen of the hydrazone linker is predicted to stabilise the 
lowest energy conformation found (Figure 4). 
 
Figure 4: Lowest energy conformation found for 11a. 
 
In order to freeze this interaction, the replacement of the hydrazone bond with an aromatic amino group 
was envisaged. This new linker was functionalised with heteroaromatic bicyclic rings, such as 2-
benzimidazole (38) and 8-quinoline (39), along with 1-naphthalene (40).  
 
2.4 Biological activity 
 
2.4.1 HCV replicon and cytostatic assay 
All the newly synthesised thieno-pyrimidines were evaluated for their potential effect against HCV 
replication in the Huh5-2 replicon system (Table 1) [42]. The HCV protease inhibitor Telaprevir (VX-
950) was included as positive control. 
 
Table 1: Antiviral effect of the test compounds on hepatitis C virus replication in the Huh5-2 replicon system. 
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Comp. R1 R2 R3 X R4 Ar EC50(M)a,d EC90(M)b,d CC50(M)c,d SIe 
1a 
SPECS 
C4H8 H N=C Me 2,5-OH-Ph <1 n.d. >141 >141 
1a 
synth. 
C4H8 H N=C Me 2,5-OH-Ph <2.2 135 >282 >128 
8a C4H8 H NH2 - - 23.1±2.71 47.4±7.51 247±115 10.7 
9a C4H8 H N=C H 2,5-OH-Ph 1.17±0.627 2.92±0.376 36.8±17.1 31.5 
10a C4H8 H N=C Me Ph 33.6 >310 53.4 1.6 
11a C4H8 H N=C Me 2-OH-Ph 2.6±1.02 20.1±27.3 154±33.3 59.2 
12a C4H8 H N=C Me 3-OH-Ph 403 >443 >443 >1.1 
13a C4H8 H N=C Me 4-OH-Ph >295 >295 >295 - 
14a C4H8 H N=C Me 2,5-OMe-Ph 53.6±32.2 n.d. 98.5±65.2 1.8 
15a C4H8 H N=C Me 2,5-Cl-Ph 9.41±2.71 55.1 >256 >27.2 
16a C4H8 H N=C Me Pyrazine 0.355±0.00526 2.85±3.69 57.1 160 
17a C4H8 H N=C Me 2-Pyridine 1.1±0.422 3.48±0.616 7.59±2.61 6.9 
18a C4H8 H N=C Me 3-Pyridine 79.4 >103 >309 3.9 
19a C4H8 H N=C Me 2-Indole 61.2±101 >277 26±10.3 0.42 
20a C4H8 H N=C Me 2-Benzimidazole 2.42±1.37 7.06±4.12 37.3 15.4 
21a C4H8 H N=C Me 2-Quinoline <0.697 n.d. 7.23 >10.4 
22a C4H8 H N=C Me 2-Pyrrole 5.26±2.11 12.8 19.5±6.73 3.7 
23a C4H8 H N=C Me 2-Furan 18.2±8.01 n.d. 58.9±12.5 3.2 
24a C4H8 H N=C Me 2-Thiophene 23±3.88 n.d. 46±7.7 2 
25a C4H8 H NHCO - 2,5-OH-Ph 0.502±0.205 0.945±0.392 99.9 199 
26a C4H8 H NHCO - 2-OH-Ph 0.273±0.0577 0.567±0.0781 63.6±12 232.9 
27a C4H8 H NHCO - 3-OH-Ph 210 >220 >294 >1.4 
28a C4H8 H NHCO - Pyrazine 1.29±0.724 3.75±3.18 10.6±6.74 8.21 
29a C4H8 H NHCO - 2-Pyridine 1.47±1.11 0.819 7.75 5.27 
30a C4H8 H NHCO - 3-Pyridine 128±11 >307 >307 2.4 
31a C4H8 H NHCO - 2-Indole 20.8±13.4 n.d. 74.5±53.9 3.6 
32a C4H8 H NHCO - 2-Benzimidazole 0.17 0.679±0.509 3.14±0.549 18.5 
33a C4H8 H NHCO - 2-Quinoline 16.5±8.7 n.d. 40.4±0.889 2.4 
34a C4H8 H NHCO - 2-Pyrrole 147±3.22 n.d. 160 1.1 
35a C4H8 H NHCO - 2-Furan 199±43.5 n.d. 230±60.3 1.2 
36a C4H8 H NHCO - 2-Thiophene 31.1±4.35 n.d. 36.7±5.54 1.2 
37 C4H8 H NHSO2 - 2-Pyridine 42.9±8.07 83.2 145 3.4 
38 C4H8 H - - 2-Benzimidazole 55.4±3.75 >104 231 4.2 
39 C4H8 H - - 8-Quinoline 186 >100 >301 >1.6 
40 C4H8 H - - 1-Naphthyl 32.4±3.8 >33.5 281 8.7 
1b C3H6 H N=C Me 2,5-OH-Ph 17.8±24.6 17.6±14.5 >367 >20.6 
11b C3H6 H N=C Me 2-OH-Ph 1.72±0.711 4.07±1.57 141±53.8 82.9 
16b C3H6 H N=C Me Pyrazine 0.688 <0.839 1.12±0.193 1.6 
17b C3H6 H N=C Me 2-Pyridine 1.18 1.44 14±14.3 11.9 
20b C3H6 H N=C Me 2-Benzimidazole 0.802 <2.24 6.83±0.329 8.3 
25b C3H6 H NHCO - 2,5-OH-Ph 2.34±0.563 3.67±1.09 198 84.6 
26b C3H6 H NHCO - 2-OH-Ph 0.221±0.092 0.352±0.00601 119 538.5 
28b C3H6 H NHCO - Pyrazine 0.0945±0.055 <0.256 2.97±1.37 31.4 
29b C3H6 H NHCO - 2-Pyridine 0.745±0.276 1.94±0.846 6.61±2.04 8.9 
32b C3H6 H NHCO - 2-Benzimidazole 0.594 1.11±0.127 7.46±3.23 11.6 
1c Me Me H N=C Me 2,5-OH-Ph 1.58±0.481 4.65±1.07 >305 >193 
11c Me Me H N=C Me 2-OH-Ph 0.384±0.079 <1.28 93.6 243.8 
28c Me Me H NHCO - Pyrazine 0.0386 0.319 1.67±0.338 43.3 
1d Me Et H N=C Me 2,5-OH-Ph 0.803 1.62±0.803 >292 >363.6 
1f H H H N=C Me 2,5-OH-Ph 2.79±1.16 4.55 226 81 
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11f H H H N=C Me 2-OH-Ph 4.69±1.53 >10.6 80.5±27.3 17.2 
16f H H H N=C Me Pyrazine 5.04 1.79 9.01±3.19 1.8 
25f H H H NHCO - 2,5-OH-Ph 2.75±0.183 9.4 >165 >60 
26f H H H NHCO - 2-OH-Ph 12±2.68 >38.8 >349 >27 
28f H H H NHCO - Pyrazine 0.851±0.117 2.28 233±22.1 274.1 
29f H H H NHCO - 2-Pyridine 0.314±0.19 0.671±0.461 138±14 445 
1g C4H4 H N=C Me 2,5-OH-Ph 0.475±0.314 0.897±0.173 21±4.58 44.2 
11g C4H4 H N=C Me 2-OH-Ph 0.0861±0.0107 0.421 11.5±2.38 133.6 
16g C4H4 H N=C Me Pyrazine 0.415 0.858 1.99 6.4 
20g C4H4 H N=C Me 2-Benzimidazole 1.1±0.429 3.25±0.732 19.1±8.28 17.4 
25g C4H4 H NHCO - 2,5-OH-Ph 0.681±0.242 2.14 46.5 68.3 
26g C4H4 H NHCO - 2-OH-Ph 0.832 1.6±0.309 108 129.8 
28g C4H4 H NHCO - Pyrazine 0.0723±0.0166 0.192±0.129 1.34±0.523 18.5 
29g C4H4 H NHCO - 2-Pyridine 0.461 1.01 1.54±0.258 3.3 
11h C4H8 Me N=C Me 2-OH-Ph 115 >94.6 >284 >2.5 
16h C4H8 Me N=C Me Pyrazine 0.069 0.24 >3 >42.7 
26h C4H8 Me NHCO - 2-OH-Ph 1.26 3.07 25 19.8 
29h C4H8 Me NHCO - 2-Pyridine 0.077 0.32 >2.95 >38.1 
11i Me Cl H N=C Me 2-OH-Ph 0.17 n.d. >9.01 >56.1 
16i Me Cl H N=C Me Pyrazine 0.058 0.289 3.13 53.9 
26i Me Cl H NHCO - 2-OH-Ph 0.159 n.d. >8.96 >56.1 
29i Me Cl H NHCO - 2-Pyridine 0.088 0.286 >9.38 >106 
VX-950 - - - - - - 0.8±0.2 - 47 58.8 
a EC50 = 50% effective concentration (concentration at which 50% inhibition of virus replication is observed). 
b EC90 = 90% effective concentration (concentration at which 50% inhibition of virus replication is observed). 
c CC50 = 50% cytostatic/cytotoxic concentration (concentration at which 50% adverse effect is observed on the host cell). 
d The EC50, EC90 and CC50 values are the mean of at least 2 independent experiments, with standard deviations of ±10% of the 
value quoted unless otherwise stated (mean value ± standard deviations). 
e
 SI = the ratio of CC50 to EC50. 
  
The presence and position of the two hydroxyl substituents in the structure of 1a seem to play an 
important role for antiviral activity, since their removal is associated with loss of activity (10a). Of 
particular importance is the hydroxyl substitution at position 2’ of the original scaffold: while 11a shows 
retained activity in comparison with 1a, 12a, with the sole 3’-hydroxy group, shows complete loss of 
antiviral potential, thus suggesting a key role for the 2’-OH. The same negative effect is observed for 
13a, where the hydroxyl function is moved to the 4’-para position of the phenyl ring. Unsubstituted 
hydrazine 8a does not show a significant antiviral effect, while removal of the phenylethylidene methyl 
group (9a) is associated with an increased cytotoxicity in comparison with 1a, with lower values of CC50 
and SI. The role of the hydroxyl substituent in the original scaffold was further explored by its 
replacement with methoxy (14a) and chloro groups (15a): these modifications are associated with 
activity reduction, thus confirming the importance of the 2’-OH group for the antiviral properties of 1a. 
The next step was the exploration of different heteroaromatic rings in the ethylidene portion of the 
molecule (16-24a): a successful replacement of the original hydroxyl functions is achieved with the 
introduction of a pyrazine (16a) and 2-benzimidazole (20a), for which the modification seems to be 
tolerated in terms of EC50. 16a shows the best activity profile found so far in this series, while 17a and 
21a, even if showing retained EC50 values, seem to be mainly cytotoxic. Comparison of the biological 
data found for 16a and 17a with 18a, in which the 3-pyridine substituent is correlated with a dramatic 
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loss of antiviral potential, suggests the same trend previously found for the aromatic hydroxyl groups 
also in the case of the heteroaromatic nitrogen in the phenylethylidene substituent: the loss of activity 
found for 18a indicates the same role for a nitrogen in position 2 and a 2’-hydroxyphenyl group. 
Furthermore, replacement of 6-membered heteroaromatic rings with 5-membered rings (22a, 23a, 24a), 
is associated with loss of activity (23a, 24a) or increased cytotoxicity (22a). 
A successful replacement of the original hydrazone group is achieved with the insertion of a hydrazide, 
as suggested by the biological data found for 25a, 26a, 28a, 29a and 32a, which all show EC50 values 
equal or below 1 M. 25a and 26a are also associated with good SI values and represent promising 
candidates for further development, while for 28a, 29a and 32a an increased cytotoxic effect can be 
observed. Results obtained for 27a, 30a, 31a, 34a, 35a and 36a, which are associated with a dramatic 
loss of activity, reveal the same trend found in the hydrazone series of compounds for the importance of 
the hydroxyl group at position 2 (25a and 26a), along with its potential replacement with heteroaromatic 
moieties with a nitrogen atom at position 2, such as pyrazine (28a) and 2-pyridine (29a), even if these 
modifications are associated with an increased cytotoxicity in this series of compounds. A second attempt 
to replace the hydrazone bond with a sulfonylhydrazide (37) led to a dramatic loss of activity. The same 
consideration can be extended to the replacement of the hydrazone linker with an amine function (38-
40), which had been rationally designed as a means to lock the internal hydrogen bond found for 11a. 
For all three compounds in this series a significant loss of activity is observed, possibly suggesting that 
some residual flexibility is important for the biological activity associated with this scaffold. 
After having confirmed the antiviral potential associated with the structure originally found and 
established a preliminary SAR for the phenylethylidene and hydrazone portions, the role of the 
tetrahydrobenzenic substituent on the thiophene ring was also explored. Six modifications were 
envisaged for this part of the molecule: an unsubstituted thieno-pyrimidine system, a cyclopentane ring 
condensed to the thiophene, an oxidised benzene substituent, two methyl groups, and finally two 
unsymmetrical substitutions, methyl-ethyl and methyl-chloro. Removal of the tetrahydrobenzene 
substituent seems to be associated with a slight decrease of activity in the hydrazone series (1f, 11f and 
18f), along with an increased cytotoxicity found for 11f and 16f. In the hydrazide series this modification 
is mainly associated with retained activity (28f, 29f) and significantly improved SI values in comparison 
with the tetrahydrobenzenic counterparts (28a, 29a), even if 26f represents an exception to this trend, 
with a forty-fold increase in EC50 in comparison with 26a. The replacement of the tetrahydrobenzene 
substituent with a cyclopentyl ring is mainly associated with retained activity, both in the hydrazone and 
hydrazide series of analogues. With the exception of 16b, which is mainly associated with a cytotoxic 
effect, and 1b, which shows a higher EC50 value than 1a and 1c, analogues 11b, 17b, 20b, 25b, 26b, 28b 
and 29b are mainly associated with a retained antiviral effect, with 26b showing the most promising 
profile in this series in terms of both EC50 and SI values. Aromatisation of the cyclohexyl ring is 
associated with a retained or improved antiviral activity in comparison with the original substituent, for 
both hydrazone and hydrazide series. With the exception of 16g and 29g, for which an increased 
cytotoxic effect is observed, retained or improved activity profiles are found for 1g, 11g, 20g, 25g, 26g 
and 28g, with EC50 values in the nanomolar range for 11g and 28g, and with a particularly interesting 
profile found for 11g and 26g,  which are associated with good SI values. These data suggest that the 
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rigidity of a tricyclic aromatic system in this part of the molecule is tolerated. Biological data found for 
1c, 11c, 28c, 1d, 11i, 16i, 26i and 29i, in which the cyclic substituent is replaced with smaller aliphatic 
or halogen groups, suggest activity retention for these three modifications: both for hydrazones (1c, 11c, 
1d, 11i and 16i) and hydrazides (28c, 26i, 29i) retained or improved EC50 and SI values are found, with 
1c, 11c, 1d showing the most promising profiles and three analogues (28c, 16i and 29i) reaching 
nanomolar EC50 values. 
A final modification on the thienopyrimidine system was planned to explore the role of the aromatic 
proton in the pyrimidine ring of 11a, through its replacement with a methyl group. Methylation of the 
pyrimidine ring is associated with an inconsistent effect among the four compounds tested: while this 
modification seems to induce activity retention for 16h, 26h and 29h, with EC50 values in the nanomolar 
range for 16h and 29h, suggesting potential for structural expansion in this part of the molecular scaffold, 
antiviral activity is completely lost in 11h, which bears a 2’-hydorxyphenyl group in the original 
hydrazone structure. 
 
2.4.2 HCV NS3 helicase enzymatic assay 
A selection among the newly synthesised thieno-pyrimidines was tested for any potential interference 
with the HCV NS3 helicase activity. In particular, interference with the enzyme unwinding activity was 
analysed for 41 new analogues (Table S2), while for 11a, 37, 26b, 11g and 28g additional studies were 
also performed, and their potential effect of the enzyme ATPase activity and binding to DNA was also 
assessed. Data for those compounds for which an IC50 can be estimated are summarised in Table 2. 
Primuline [43] and aurintricarboxylic acid [44] were included as positive controls. 
 
Table 2: Inhibition of HCV NS3 helicase activity for the newly synthesised thieno-pyrimidine derivatives. 
Compound IC50(M) 
 Unwinding ATPase (w RNA)a ATPase (no RNA)a DNA bindinga 
11a >1000 780 ± 50 760 ±40 >1000 
31a 224 n.d n.d. n.d. 
37 >1000 >1000 n.d. 675 ± 240 
26b 250 333 >1000 >1000 
1f 229 n.d n.d. n.d. 
11g >1000 >1000 n.d. 827 ± 220 
28g >1000 >1000 n.d. 949 ± 130 
26i 306 n.d n.d. n.d. 
Primuline 10±2 40±12 >200 46±10 
Aurintricarboxylic 
Acid 
0.3± 0.1 5.1±2.7 3.3±1.7 2.0±0.9 
a The IC50 values are the mean ± standard deviations of at least 2 independent experiments. 
 
Despite the fact that 31a, 26b, 1f and 26i show some inhibition of the HCV NS3 helicase unwinding 
activity at high concentrations, a trend for this effect cannot be identified as it does not seem to be 
correlated with any specific structural feature. 26b was also found to show inhibition of the enzyme 
ATPase activity at high concentrations, and this effect can be observed also for 11a, while 37, 11g and 
28g were identified as weak inhibitors of DNA binding. Considering all three effect examined, the 
observed IC50 values are dramatically higher than the range of activities found in the HCV replicon assay 
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for most of the compounds tested. The lack of correlation between the two sets of data suggests that the 
antiviral effect of the thieno-pyrimidine structures presented in this study is probably due to a different 
target, viral or cellular, other than the HCV NS3 helicase. It should also be noted that evaluation of 
QU663 in similar enzymatic assays did not reveal any significant interference with the helicase ATPase 
or unwinding activity also for this reference compound [43]. 
 
3 Conclusions 
Starting from a computer-based approach, a substituted thieno-pyrimidine scaffold was identified as 
promising inhibitor of the HCV replication in the subgenomic replicon assay. Its structure was the 
starting point for the design and synthesis of different series of new analogues, with which the antiviral 
potential originally found was confirmed and improved. Several new derivatives were found to be 
associated with EC50 values in the sub-micromolar or nanomolar range, and different among them are 
also associated with good SI values. Structure-activity relationships were identified for the biological 
effect of the scaffold originally found: the presence of a hydrazone linker is essential for antiviral activity, 
but this group can be successfully replaced with a more stable hydrazide. In order to retain activity, both 
hydrazone and hydrazide linkers need functionalisation with a six-membered aromatic ring carrying a 
hydroxyl group at position 2, or a heteroaromatic ring with a nitrogen atom at position 2. The presence 
of an aliphatic or aromatic substituent in the thienopyrimidine nucleus appears to be beneficial for 
activity, and suggests expansion potential in this part of the structure. The role of the pyrimidine proton 
has also been explored: its replacement with a methyl group is mainly associated with activity retention, 
suggesting also in this case the potential for structural expansion. Preliminary enzymatic evaluations 
suggest that the antiviral effect associated with the newly prepared compounds is mainly unrelated to the 
interference with the NS3 helicase activity, and other viral or cellular targets are likely involved. 
Understanding the biological target and the mechanism of action of these structures, along with in vitro 
pre-clinical studies on the most promising new analogues found (11a, 16a, 25a, 26b, 1c, 11c, 1d, 28f, 
29f, 11g, 26g), will be the main focus of future studies.  
 
4 Experimental 
 
4.1 Synthetic chemistry methods 
All solvents used for chromatography were HPLC grade from Fisher Scientific (UK). 1H and 13C NMR 
spectra were recorded with a Bruker Avance DPX500 spectrometer operating at 500 and 125 MHz, with 
Me4Si as internal standard. Mass spectra were determined with a Bruker microTOF spectrometer using 
electrospray ionization (ESI source). For mass spectra, solutions were made in HPLC grade methanol. 
Flash column chromatography was performed with silica gel 60 (230–400mesh) (Merck) and TLC was 
carried out on precoated silica plates (kiesel gel 60 F254, BDH). Compounds were visualised by 
illumination under UV light (254 nm). Melting points were determined on an electrothermal instrument 
and are uncorrected. All solvents were dried prior to use and stored over 4 Å molecular sieves, under 
nitrogen. All final compounds were more than 95% pure. 
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Intermediates 5-8 were generally prepared according to literature procedures, which are described in 
detail along with compound characterisation in the Supporting Information. Details for the preparation 
and full characterisation of the new target compounds 9-40 are given below. 
 
4.1.1 General method for the preparation of (thieno[2,3-d]pyrimidin-4-yl)-hydrazones 1, 9-26 
The different (thieno[2,3-d]pyrimidin-4-yl)-hydrazine (8a-d or f-i) (1 eq.) and arylketone or aldheyde 
(1.2) were dissolved in EtOH (12 mL/mmol eq.), and the mixture was refluxed for 24 h. The reaction 
mixture was then cooled to r.t and placed in a fridge o.n. The resulting precipitate was filtered, washed 
with a cold solution of 80% EtOH in water and crystallised from EtOH unless otherwise stated. 
Most hydrazone products show two sets of signals in NMR experiments. All 1H-NMR spectra of the new 
hydrazone compounds are reported for clarity in the Supporting Information. 
 
4.1.1.1 2-{1-[(5,6,7,8-Tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazono]-ethyl}-benzene-
1,4-diol (1a) 
Obtained in 66% yield as a yellow solid. M.p. >300 °C. Two sets of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : (first set) 1.83 (broad s, 4H), 2.45 (s, 3H), 2.76 (broad s, 2H), 3.01 
(broad s, 2H,), 6.75 (broad s, 2H), 6.99 (broad s, 1H), 7.72 (broad s, 1H), 8.86 (broad s, 1H), 11.39 (broad 
s, 1H), 11.73 (broad s, 1H). 1H-NMR (DMSO-d6), : (second set) 1.83 (broad s, 4H), 2.45 (s, 3H), 2.84 
(broad s, 2H), 3.17 (broad s, 2H), 6.75 (broad s, 2H), 6.99 (broad s, 1H), 8.52 (broad s, 1H), 8.86 (broad 
s, 1H), 9.36 (broad s, 1H), 12.58 (broad s, 1H). 13C-NMR (DMSO-d6), : (first and second set) 12.9, 
13.3, 22.0, 22.2, 24.7, 26.4, 113.4, 114.1, 116.9, 117.6, 118.1, 119.4, 121.0, 126.2, 130.7, 132.5, 133.8, 
143.96, 145.2, 149.2, 150.9, 152.5, 153.82, 154.4, 156.5, 162.9, 165.7. MS [ESI, m/z]: 377 [M+Na]. 
Anal. Calcd for C18H18N4O2S: C, 61.00; H, 5.12; N, 15.81. Found: C, 61.15; H, 5.38; N, 15.91. 
 
4.1.1.2 2-[(5,6,7,8-Tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazonomethyl]-benzene-1,4-
diol (9a)  
Obtained in 61% yield as a yellow solid. M.p. 235-237 °C. Two sets of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : (first set) 1.75-1.88 (broad m, 4H), 2.71-2.86 (broad m, 2H), 2.97-
3.14 (broad m, 2H), 6.71-6.76 (m, 2H), 7.19 (s, 1H), 7.76 (s, 1H), 8.54 (s, 1H), 8.91 (broad s, 1H), 9.60 
(broad s, 1H), 11.48 (broad s, 1H). 1H-NMR (DMSO-d6), : (second set) 1.75-1.88 (broad m, 4H), 2.71-
2.86 (broad m, 2H), 2.97-3.14 (mb, 2H), 6.71-6.76 (m, 2H), 6.92 (s, 1H), 8.48 (s, 1H), 8.54 (s, 1H), 8.91 
(broad s, 1H), 10.09 (broad s, 1H), 10.75 (broad s, 1H). 13C-NMR (DMSO-d6), : (first and second set) 
21.9, 22.1, 22.3, 24.6, 25.0, 25.5, 26.5, 114.1, 114.4, 116.6, 116.9, 118.3, 118.6, 118.8, 119.4, 120.4, 
126.4, 130.8, 132.2, 133.1, 143.9, 146.4, 147.5, 149.8, 149.9, 152.5, 153.3, 156.9. MS [ESI, m/z]: 341 
[M+H]. Anal. Calcd for C17H16N4O2S: C, 59.98; H, 4.74; N, 16.46. Found: C, 59.64; H, 5.89; N, 16.43. 
 
4.1.1.3 N-(1-Phenyl-ethylidene)-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-
hydrazine (10a) [38] 
Obtained in 62% yield as yellow crystals. M.p. 190-192 °C (lit. 150-152 °C [33]). Two sets of signals 
observed in NMR expriments. 1H-NMR (CDCl3), : (first set) 1.85-1.91 (m, 4H), 2.55 (s, 3H), 2.79-2.82 
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(m, 2H), 3.10-3.14 (m, 2H), 7.38-7.43 (m, 5H), 7.66 (s, 1), 10.36 (broad s, 1H). 1H-NMR (CDCl3), : 
(second set) 1.94-2.06 (m, 4H), 2.38 (s, 3H), 2.86-2.90 (m, 2H), 3.04-3.07 (m, 2H), 7.83-7.87 (m, 5H), 
8.50 (broad s, 1H), 8.64 (s, 1H). 13C-NMR (CDCl3), : (first and second set) 13.5, 15.1, 22.2, 22.3, 22.6, 
22.7, 25.3, 25.4, 26.6, 26.7, 120.5, 124.5, 126.5, 126.7, 128.4, 129.1, 129.2, 129.5, 129.8, 131.4, 133.7, 
134.4, 135.8, 135.3, 137.9, 139.3, 141.3, 148.0, 149.2, 153.4, 156.7, 159.5. MS [ESI, m/z]: 345. [M+Na]. 
Anal. Calcd for C18H18N4S: C, 67.05; H, 5.63; N, 17.38. Found: C, 67.02; H, 5.95; N, 17.37. 
 
4.1.1.4 2-{1-[(5,6,7,8-Tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazono]-ethyl}-phenol 
(11a)  
Obtained in 98% yield as a pale yellow solid. M.p. 250-252°C. Two sets of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : (first set) 1.76-1.91 (broad m, 4H), 2.49 (s, 3H), 2.73-2.85 (broad 
m, 2H), 2.97-3.01 (m, 2H), 6.89-6.93 (m, 2H), 7.27-7.31 (m, 1H), 7.60-7.63 (m, 1H), 7.77 (s, 1H), 11.43 
(broad s, 1H), 12.50 (broad s, 1H). 1H-NMR (DMSO-d6), : (second set) 1.76-1.91(broad m, 4H), 2.49 
(s, 3H), 2.73-2.85 (broad m, 2H), 3.16-3.19 (broad m, 2H), 6.89-6.93 (m, 2H), 7.27-7.31 (m, 1H), 7.64-
7.67 (m, 1H), 8.53 (s, 1H), 9.38 (broad s, 1H), 13.33 (broad s, 1H). 13C-NMR (DMSO-d6), : (first and 
second set) 12.9, 14.8, 22.0, 22.3, 24.6, 25.0, 26.5, 116.5, 117.2, 118.6, 119.4, 120.9, 126.3, 128.0, 128.7, 
130.6, 132.6, 133.9, 144.0, 145.3, 152.6, 153.9, 156.6, 158.2, 163.2. MS [ESI, m/z]: 339 [M+H]. Anal. 
Calcd for C18H18N4OS: C, 63.88; H, 5.36; N, 16.56. Found: C, 63.75; H, 5.64; N, 16.51. 
 
4.1.1.5 3-{1-[(5,6,7,8-Tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazono]-ethyl}-phenol 
(12a)  
Obtained in 99% yield as a light orange solid. M.p. 307-309°C. Single set of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : 1.76-1.84 (m, 4H), 2.40 (s, 3H), 2.73-2.76 (m, 2H), 3.01-3.05 (m, 
2H), 6.79-6.83 (m, 1H), 7.19-7.22(m, 1H), 7.37-7.39 (m, 1H), 7.49 (d, J= 7.9 Hz, 1H), 7.76 (s, 1H), 9.39 
(broad s, 1H), 11.54 (broad s, 1H). 13C-NMR (DMSO-d6), : 14.4, 22.1, 22.3, 24.6, 26.4, 113.5, 115.9, 
117.5, 119.6, 128.8, 130.8, 132.2, 140.1, 144.0, 147.2, 156.7, 157.1, 157.7. MS [ESI, m/z]: 339 [M+H]. 
Anal. Calcd for C18H18N4OS: C, 63.88; H, 5.36; N, 16.56. Found: C, 64.04; H, 5.31; N, 16.66. 
 
4.1.1.6 4-{1-[(5,6,7,8-Tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazono]-ethyl}-phenol 
(13a)  
Obtained in 66% yield as an orange solid. M.p. 263-265°C. Single set of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : 1.74-1.83 (m, 4H), 2.39 (s, 3H), 2.71-2.75 (m, 2H), 2.99-3-03 (m, 
2H), 6.80 (d, J= 8.7 Hz, 2H), 7.74 (s, 1H), 7.90 (d, J= 8.7 Hz, 2H), 9.68 (broad s, 1H), 11.48 (broad s, 
1H). 13C-NMR (DMSO-d6), : 14.0, 22.1, 22.4, 24.6, 26.3, 114.8, 119.6, 128.1, 129.7, 130.8, 131.9, 
144.0, 146.7, 156.3, 157.4, 158.5. MS [ESI, m/z]: 339 [M+H]. Anal. Calcd for C18H18N4OS: C, 63.88; 
H, 5.36; N, 16.56. Found: C, 64.08; H, 5.83; N, 16.67. 
 
4.1.1.7 4-(2-(1-(2,5-Dimethoxyphenyl)ethylidene)hydrazinyl)-5,6,7,8-tetrahydrobenzo [4,5]thieno[2,3-
d]pyrimidine (14a)  
Purified by crystallisation from DCM/n-hexane. Obtained in 61% yield as a grey solid. M.p. 143-145 °C.  
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Two sets of signals observed in NMR experiments. 1H-NMR (DMSO-d6), : (first set) 1.57-1.63 (m, 
2H), 1.68-1.77 (m, 2H), 2.10-2.15 (m, 2H), 2.29 (s, 3H), 2.69-2.75 (m, 2H), 3.75 (s, 3H), 3.76 (s, 3H), 
6.91-6.95 (m, 1H), 7.06-7.12 (m, 1H), 7.18 (d, J= 9.0 Hz, 1H), 8.38 (s, 1H), 8.40 (bs). 1H-NMR (DMSO-
d6), : (second set) 1.45-1.51 (m, 2H), 1.68-1.77 (m, 2H), 2.29 (s, 3H), 2.32-2.39 (m, 2H), 2.61-2.65 (m, 
2H), 3.65 (s, 3H), 3.69 (s, 3H), 6.70-6.73 (m, 1H), 6.83-6.87 (m, 1H), 6.91-6.95 (m, 1H), 7.63 (s, 1H), 
11.43 (broad s, 1H). 13C-NMR (DMSO-d6), : (first and second set) 21.7, 21.8, 22.3, 23.8, 23.9, 24.4, 
24.7, 24.8, 25.8, 55.4, 55.6, 55.8, 56.2, 112.1, 113.4, 113.5, 114.3, 114.3, 114.6, 115.9, 119.2, 123.4, 
125.0, 129.3, 130.8, 131.5, 133.3, 143.8, 145.6, 148.8, 149.4, 150.4, 152.5, 152.7, 153.2, 153.8, 155.8, 
157.8, 165.2. MS [ESI, m/z]: 383 [M+H]. Anal. Calcd for C20H22N4O2S: C, 62.80; H, 5.80; N, 14.65. 
Found: C, 62.48; H, 6.12; N, 14.58. 
 
4.1.1.8 N-[1-(2,5-Dichloro-phenyl)-ethylidene]-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno [2,3-
d]pyrimidin-4-yl)-hydrazine (15a)  
Purified by flash column chromatography eluting with n-hexane-EtOAc 100:0 v/v increasing to 70:30 
v/v. Obtained in the 46% yield as a yellow solid. TLC (1:1 n-hexane –EtOAc, Rf: 0.57). M.p. 82-84 °C. 
Single set of signals observed in NMR experiments. 1H-NMR (DMSO-d6), : 1.76-1.84 (m, 4H), 2.38 (s, 
3H), 2.74-2.77 (m, 2H), 3.01-3.04 (m, 2H), 7.49 (dd, J1= 8.6 Hz, J2= 2.5 Hz, 1H), 7.55 (d, J= 8.6 Hz, 
1H), 7.61 (d, J= 2.5 Hz, 1H), 7.71(s, 1H), 11.58 (broad s, 1H). 13C-NMR (DMSO-d6), : 18.4, 22.1, 22.3, 
24.6, 26.3, 119.2, 129.4, 130.0, 130.3, 130.8, 131.3, 131.6, 132.4, 141.3, 143.7, 148.2, 157.2, 157.6. MS 
[ESI, m/z]: 391, 393 [M+H]. Anal. Calcd for C18H16Cl2N4S: C, 55.25; H, 4.12; N, 14.32. Found: C, 
55.21; H, 4.23; N, 14.27. 
 
4.1.1.9 N-(1-Pyrazin-2-yl-ethylidene)-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-
hydrazine (16a) 
Obtained in 55% yield as a yellow solid.  M.p. 201-203 °C. Two sets of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : (first set) 1.86-191 (m, 4H), 2.59 (s, 3H), 2.78-2.82 (m, 2H), 3.10-
3.13 (m, 2H), 7.73 (d, J= 1.6 Hz, 1H), 8.46 (d, J= 2.7 Hz, 1H), 8.53 (dd, J1= 2.7 Hz, J2= 1.6 Hz, 1H), 9.32 
(s, 1H), 10.56 (broad s, 1H). 1H-NMR (DMSO-d6), : (second set) 1.93-1.98 (m, 2H), 1.99-2.05 (m, 2H), 
2.49 (s, 3H), 2.86-2.90 (m, 2H), 3.05-3.08 (m, 2H), 8.50-8.52 (m, 2H), 8.66 (s, 1H), 8.73 (broad s, 1H), 
9.51 (s, 1H). 13C-NMR (DMSO-d6), : (first and second set) 10.8, 13.4, 22.3, 22.6, 22.7, 22.8, 25.3, 25.6, 
26.6, 26.6, 116.2, 120.5, 124.3, 131.4, 134.3, 136.0, 141.1, 142.8, 142.9, 143.2, 143.3, 143.4, 143.8, 
147.6, 149.0, 150.4, 152.0, 153.0, 153.7, 157.9, 158.3, 167.3. MS [ESI, m/z]: 325 [M+H]. Anal. Calcd 
for C16H16N6S: C, 59.24; H, 4.97; N, 25.89. Found: C, 59.14, H, 4.79, N, 25.95. 
 
4.1.1.10 N-(1-Pyridin-2-yl-ethylidene)-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-
hydrazine (17a) 
Purified by crystallisation from EtOH/H2O. Obtained in 81% yield as an orange solid. M.p. 195-197 °C. 
Two sets of signals observed in NMR experiments. 1H-NMR (DMSO-d6), : (first set) 1.75-1.81 (m, 
4H), 2.54 (s, 3H), 2.71-2.74 (m, 2H), 2.99-3.03 (m, 2H), 7.36 (dd, J1= 7.5 Hz, J2= 5.1 Hz, 1H), 7.79-7.83 
(m, 2H), 8.53 (d, J= 8.0 Hz, 1H), 8.57-8.61 (m, 1H), 11.74 (broad s, 1H). 1H-NMR (DMSO-d6), : 
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(second set) 1.82-1.86 (m, 2H), 1.91-1.97 (m, 2H), 2.42 (s, 3H), 2.75-2.78 (m, 2H), 3.06-3.09 (m, 2H), 
7.52 (dd, J1= 7.8 Hz, J2= 5.1 Hz, 1H), 7.74 (d, J= 8.0 Hz, 1H), 8.01-8.03 (m, 1H), 8.41 (s, 1H), 8.57-8.61 
(m, 1H), 9.73 (broad s, 1H). 13C-NMR (DMSO-d6), : (first and second set) 13.1, 21.8, 22.1, 22.2, 22.3, 
24.6, 24.9, 26.1, 26.3, 119.6, 120.8, 123.5, 124.0, 124.3, 130.8, 132.4, 132.7, 135.8, 143.8, 147.1, 148.0, 
148.4, 156.0, 157.3, 158.6. MS [ESI, m/z]: 324 [M+H]. Anal. Calcd for C17H17N5S: C, 63.13; H, 5.30; 
N, 21.65. Found: C, 63.20; H, 5.55; N, 21.60. 
 
4.1.1.11 4-(2-(1-(Pyridin-3-yl)ethylidene)hydrazinyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno [2,3-
d]pyrimidine (18a)  
Obtained in 61% yield as yellow crystals. M.p. 188-191 °C. Single set of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : 1.76-1.83 (m, 4H), 2.46 (s, 3H), 2.73-2.76 (m, 2H), 3.01-3.05 (m, 
2H), 7.42-7.45 (m, 1H), 7.80 (d, J= 3.6 Hz, 1H), 8.33-8.36 (m, 1H), 8.57 (dd, J1= 4.7 Hz, J2= 1.5 Hz, 
1H), 9.28 (s, 1H), 11.74 (broad s, 1H). 13C-NMR (DMSO-d6), : 13.8, 22.1, 22.3, 24.6, 26.3, 119.5, 
123.1, 130.8, 132.4, 133.6, 133.9, 143.9, 147.8, 148.0, 149.4, 155.4, 157.2. MS [ESI, m/z]: 324 [M+H].  
Anal. Calcd for C17H17N5S: C, 63.13; H, 5.30; N, 21.65. Found: C, 63.32; H, 5.51; N, 21.73. 
 
4.1.1.12 N-[1-(1H-Indol-2-yl)-ethylidene]-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-
yl)-hydrazine (19a)  
Obtained in 53% yield as a yellow solid. M.p. 213-215°C. Single set of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : 1.77-1.85 (m, 4H), 2.41 (s, 3H), 2.74-2.78 (m, 2H), 3.00-3.06 (m, 
2H), 6.87 (s, 1H), 7.01-7.03 (m, 1H), 7.18-7.20 (m, 1H), 7.44 (d, J= 7.9 Hz, 1H), 7.96 (d, J= 7.9 Hz, 1H), 
7.96 (s, 1H), 11.35 (broad s, 1H), 11.98 (broad s, 1H). 13C-NMR (DMSO-d6), : 13.5, 22.1, 22.3, 24.6, 
26.3, 103.3, 110.9, 119.1, 119.6, 120.7, 123.0, 128.1, 130.8, 132.4, 136.8, 137.7, 143.5, 147.9, 150.3, 
156.9. MS [ESI, m/z]: 362 [M+H]. Anal. Calcd for C20H19N5S: C, 66.46; H, 5.30; N, 19.37. Found: C, 
66.74; H, 5.51; N, 19.27. 
 
4.1.1.13 N-[1-(1H-Benzoimidazol-2-yl)-ethylidene]-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno [2,3-
d]pyrimidin-4-yl)-hydrazine (20a)  
Obtained in 42% yield as a light brown solid. M.p. 287-289 °C. Two sets of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : (first set) 1.74-1.84 (m, 4H), 2.72-2.81 (m, 2H), 3.01-3.08 (m, 
2H), 3.18 (s, 3H), 7.17-7.23 (m, 1H), 7.25-7.31 (m, 1H), 7.54-7.61 (m, 1H), 7.63-7.73 (m, 1H), 8.04 (s, 
1H), 12.10 (broad s, 1H), 12.57 (broad s, 1H). 1H-NMR (DMSO-d6), : (second set) 1.91-1.96 (m, 2H), 
2.02-2.10 (m, 2H), 2.83-2.87 (m, 2H), 3.42-3.46 (m, 2H), 4.08 (s, 3H), 7.36-7.43 (m, 2H), 7.63-7.73 (m, 
2H, H), 8.50 (s, 1H), 13.03 (broad s, 1H), 14.31 (broad s, 1H). 13C-NMR (DMSO-d6), : (first and second 
set) 13.1, 22.0, 22.3, 24.6, 26.2, 48.5, 111.0, 119.3, 119.5, 121.4, 123.5, 130.8, 132.9, 133.5, 143.4, 143.7, 
149.2, 149.7, 151.7, 157.9. MS [ESI, m/z]: 363 [M+H]. Anal. Calcd for C19H18N6S: C, 62.96; H, 5.01; 
N, 23.19. Found: C, 62.85; H, 4.85; N, 23.37. 
 
4.1.1.14 4-(2-(1-(Quinolin-2-yl)ethylidene)hydrazinyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno [2,3-
d]pyrimidine (21a) 
 17 
Purified by crystallisation from EtOH/H2O. Obtained in 71% yield as an orange solid. M.p. 21-123 °C. 
Single set of signals observed in NMR experiments. 1H-NMR (DMSO-d6), : 1.79-1.83 (m, 4H), 2.62 (s, 
3H), 2.74-2.78 (m, 2H), 3.05-3.09 (m, 2H), 7.58-7.61 (m, 1H), 7.74-7.78 (m, 1H), 7.89 (s, 1H), 7.94 (d, 
J= 8.3 Hz, 1H), 8.04 (d, J= 8.3 HZ, 1H), 8.34 (d, J= 8.7 Hz, 1H), 8.77 (d, J= 8.7 Hz, 1H), 11.90 (broad 
s, 1H). 13C-NMR (DMSO-d6), : 12.9, 22.1, 22.3, 24.7, 26.3, 119.2, 119.5, 126.6, 127.6, 127.7, 129.0, 
129.4, 130.9, 132.7, 135.2, 143.8, 146.9, 148.4, 156.2, 158.0, 159.1. MS [ESI, m/z]: 374 [M+H]. Anal. 
Calcd for  C21H19N5S: C, 67.53; H, 5.13; N, 18.75. Found: C, 67.31; H, 5.36; N, 18.62. 
 
4.1.1.15 4-(2-(1-(1H-Pyrrol-2-yl)ethylidene)hydrazinyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno [2,3-
d]pyrimidine (22a) 
Obtained in 62% yield as a yellow solid. M.p. 84-89 °C. Two sets of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : (first set) 1.76-1.86 (broad m, 4H), 2.27 (s, 3H), 2.71-2.75 (broad 
m, 2H), 2.97-3.01 (broad m, 2H), 6.11-6.14 (m, 1H), 6.47-6.49 (m, 1H), 7.00-7.02 (m, 1H), 7.82 (s, 1H), 
11.31 (broad s, 1H), 11.80 (broad s, 1H).
 
1H-NMR (DMSO-d6), : (second set) 1.87-1.89 (broad m, 4H), 
2.33 (s, 3H), 2.71-2.75 (broad m, 2H), 3.05-3.09 (broad m, 2H), 6.18 (m, 1H), 6.60 (m, 1H), 7.13 (m, 
1H), 7.82 (s, 1H), 11.80 (broad s, 1H), 12.15 (broad s, 1H).
 
13C-NMR (DMSO-d6), : (first and second 
set) 13.4, 22.1, 22.4, 24.6, 26.2, 108.7, 110.2, 119.7, 120.7, 130.8, 131.8, 131.9, 143.6, 146.8, 150.4, 
156.1. MS [ESI, m/z]: 312 [M+H]. Anal. Calcd for  C16H17N5S: C, 61.71; H, 5.50; N, 22.49. Found: C, 
61.57; H, 5.38; N, 22.59. 
 
4.1.1.16 4-(2-(1-(Furan-2-yl)ethylidene)hydrazinyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-
d]pyrimidine (23a)  
Obtained in 36% yield as a yellow solid. M.p. 134-139 °C. Single set of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : 1.75-1.82 (m, 4H), 2.33 (s, 3H), 2.72-2.75 (m, 2H), 2.98-3.01 (m, 
2H), 6.63 (dd, J1= 3.4 Hz, J2= 1.7 Hz, 1H), 7.08 (d, J= 3.4 Hz, 1H), 7.76-7.79 (m, 2H), 11.47 (broad s, 
1H). 13C-NMR (DMSO-d6), : 13.7, 22.1, 22.3, 24.6, 26.3, 109.9, 111.9, 119.5, 130.8, 132.3, 143.8, 
143.9, 147.3, 149.5, 153.3, 156.8. MS [ESI, m/z]: 313 [M+H]. Anal. Calcd for  C16H16N4OS: C, 61.52; 
H, 5.16; N, 17.39. Found: C, 61.71; H, 4.97; N, 17.52. 
 
4.1.1.17 4-(2-(1-(Thiophen-2-yl)ethylidene)hydrazinyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno [2,3-
d]pyrimidine (24a) 
Obtained in 44% yield as yellow crystals. M.p. 129-132 °C. Single set of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : 1.76-1.83 (m, 4H), 2.42 (s, 3H), 2.72-2.75 (m, 2H), 2.98-3.01 (m, 
2H), 7.11 (dd, J1= 5.2 Hz, J2= 3.7 Hz, 1H), 7.51 (dd, J1= 3.7 Hz, J2= 0.9 Hz, 1H), 7.58 (dd, J1= 5.2 Hz, 
J2= 0.9 Hz, 1H), 7.80 (s, 1H), 11.24 (broad s, 1H). 13C-NMR (DMSO-d6), : 14.9, 22.1, 22.3, 24.6, 26.3, 
119.5, 127.0, 127.5, 127.9, 130.8, 132.3, 144.0, 144.4, 146.8, 153.7, 156.7. MS [ESI, m/z]: 329 [M+H]. 
Anal. Calcd for C16H16N4S2 (328.4): C, 58.51; H, 4.91; N, 17.06. Found: C, 58.70; H, 5.17; N, 17.15. 
 
4.1.1.18 2-{1-[(2,3-Dihydro-1H-8-thia-5,7-diaza-cyclopenta[a]inden-4-yl)-hydrazono]-ethyl}-benzene-
1,4-diol (1b)  
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Obtained in 74% yield as a yellow solid. M.p. 308-310 °C. Two sets of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : (first set) 2.41 (s, 3H), 2.44-2.49 (m, 2H), 2.98-3.02 (m, 2H), 3.17-
3.21 (m, 2H), 6.74-6.76 (m, 2H), 6.98-7.00 (m, 1H), 8.52 (s, 1H), 8.88 (broad s, 1H), 9.51 (broad s, 1H), 
12.38 (broad s, 1H). 1H-NMR (DMSO-d6), : (second set) 2.41 (s, 3H), 2.44-2.49 (m, 2H), 2.90-2.94 (m, 
2H), 3.17-3.21 (m, 2H), 6.74-6.76 (m, 2H), 6.98-7.00 (m, 1H), 7.73 (s, 1H), 8.88 (broad s, 1H), 11.54 
(broad s, 1H), 11.79 (broad s, 1H). 13C-NMR (DMSO-d6), : (first and second set) 13.0, 14.4, 27.3, 28.6, 
29.0, 29.3, 29.5, 112.9, 113.5, 114.1, 116.9, 117.6, 118.0, 118.2, 119.7, 135.4, 139.2, 143.8, 144.7, 149.1, 
151.0, 152.5, 153.5, 154.9, 171.3. MS [ESI, m/z]: 341 [M+H]. Anal. Calcd for C17H16N4O2S: C, 59.98; 
H, 4.74; N, 16.46. Found: C, 59.71; H, 5.01; N, 16.39. 
 
4.1.1.19 2-{1-[(2,3-Dihydro-1H-8-thia-5,7-diaza-cyclopenta[a]inden-4-yl)-hydrazono]-ethyl}-phenol 
(11b) 
Obtained in 71% yield as a pale yellow solid. M.p. 267-269 °C. Two sets of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : (first set) 2.37-2.48 (broad m, 5H), 2.98-3.07 (broad m, 2H), 3.18-
3.25 (broad m, 2H), 6.88-6.92 (m, 2H), 7.27-7.32 (m, 1H), 7.59-7.67 (m, 1H), 8.54 (s, 1H), 9.59 (broad 
s, 1H), 13.16 (broad s, 1H). 1H-NMR (DMSO-d6), : (second set) 2.37-2.48 (broad m, 5H), 2.90-2.94 
(broad m, 2H), 2.98-3.07 (broad m, 2H), 6.88-6.92 (m, 2H), 7.27-7.32 (m, 1H), 7.59-7.67 (m, 1H), 7.75 
(s, 1H), 11.49 (broad s, 1H), 12.55 (broad s, 1H). 13C-NMR (DMSO-d6), : (first and second set) 13.0, 
14.4, 27.3, 28.6, 29.1, 29.3, 29.5, 112.9, 116.5, 117.2, 118.5, 119.6, 135.4, 128.1, 128.7, 130.8, 135.4, 
139.3, 143.8, 152.5, 153.7, 155.4, 158.31. MS [ESI, m/z]: 325 [M+H]. Anal. Calcd for C17H16N4OS: C, 
62.94; H, 4.97; N, 17.26. Found: C, 62.92; H, 4.83; N, 17.36. 
 
4.1.1.20 4-(2-(1-(Pyrazin-2-yl)ethylidene)hydrazinyl)-6,7-dihydro-5H-cyclopenta[4,5] thieno[2,3-
d]pyrimidine (16b) 
Obtained in 42% yield as a yellow solid. M.p. 182-185 °C. Two sets of signals observed in NMR 
eperiments. 1H-NMR (CDCl3), : (first set) 2.48-2.56 (m, 5H), 3.05-3.09 (m, 2H), 3.11-3.17 (m, 2H), 
8.53-8.56 (m, 3H), 8.61 (s, 1H), 9.40 (d, J= 1.4 Hz, 1H). 1H-NMR (CDCl3), : (second set) 2.48-2.56 (m, 
2H), 2.61 (s, 3H), 2.97-3.01 (m, 2H), 3.11-3.17 (m, 2H), 7.75 (s, 1H), 8.49 (d, J= 2.5 Hz, 1H), 8.53-8.56 
(m, 1H), 9.34 (d, J= 1.4 Hz, 1H), 10.39 (broad s, 1H). 13C-NMR (CDCl3), : (first and second set) 10.6, 
13.0, 27.9, 28.1, 29.7, 29.8, 29.9, 30.9, 113.5, 134.8, 140.8, 141.2, 142.9, 143.0, 143.2, 143.3, 143.4, 
143.7, 147.3, 150.5, 152.3, 153.8, 173.6. MS [ESI, m/z]: 311 [M+H]. Anal. Calcd for C15H14N6S: C, 
58.05; H, 4.55; N, 27.08. Found: C, 57.91; H, 4.89; N, 27.05. 
 
4.1.1.21 4-(2-(1-(Pyridin-2-yl)ethylidene)hydrazinyl)-6,7-dihydro-5H-cyclopenta[4,5] thieno[2,3-
d]pyrimidine (17b) 
Obtained in 36% yield as an orange solid. M.p. 155-157 °C. Two sets of signals observed in NMR 
experiments. 1H-NMR (CDCl3), : (first set) 2.59 (s, 3H), 2.60-2.65 (m, 2H), 3.04-3.08 (m, 2H), 3.31-
3.35 (m, 2H), 7.40-7.43 (m, 1H), 7.62-7.64 (m, 1H), 7.91-7.95 (m, 1H), 8.65 (s, 1H), 8.68-8.70 (m, 1H), 
15.07 (broad s, 1H). 1H-NMR (CDCl3), : (second set) 2.54 (s, 3H), 2.49-2.57 (m, 2H), 3.04-3.08 (m, 
2H), 3.12-3.16 (m, 2H), 7.27-7.29 (m, 1H), 7.71-7.75 (m, 1H), 8.20-8.22 (m, 1H), 8.48 (broad s, 1H), 
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8.61 (s, 1H), 8.62-8.63 (m, 1H). 13C-NMR (CDCl3), : (first and second set) 10.9, 22.6, 27.9, 27.9, 29.8, 
29.8, 30.5, 113.5, 121.2, 123.6, 123.7, 123.7, 134.9, 136.2, 137.7, 139.4, 139.8, 140.6, 146.9, 148.5, 
149.7, 152.6, 153.4, 153.6, 153.9, 155.0, 172.4. MS [ESI, m/z]: 310 [M+H]. Anal. Calcd for  C16H15N5S: 
C, 62.11; H, 4.89; N, 22.64. Found: C, 61.97; H, 5.02; N, 22.59. 
 
4.1.1.22 4-(2-(1-(1H-Benzo[d]imidazol-2-yl)ethylidene)hydrazinyl)-6,7-dihydro-5H-cyclopenta[4,5] 
thieno[2,3-d]pyrimidine (20b)  
Obtained in 58% yield as a light brown solid. M.p. charring > 230 °C. Two sets of signals observed in 
NMR experiments. 1H-NMR (DMSO-d6), : (first set) 2.36-2.42 (m, 2H), 2.52 (s, 3H), 2.89-2.94 (m, 
2H), 2.99-3.07 (m, 2H), 7.16-7.24 (m, 2H), 7.52-7.60 (m, 1H), 7.62-7.71 (m, 1H), 8.04 (s, 1H), 12.09 
(broad s, 1H), 12.54 (broad s, 1H). 1H-NMR (DMSO-d6), : (second set) 2.29-2.33 (m, 2H), 2.52 (s, 3H), 
2.89-2.94 (m, 2H), 2.99-3.07 (m, 2H), 7.35-7.41 (m, 2H), 7.62-7.71 (m, 1H), 7.73-7.76 (m, 1H), 8.47 (s, 
1H), 13.00 (broad s, 1H), 14.40 (broad s, 1H). 13C-NMR (DMSO-d6), : (first and second set) 12.6, 18.5, 
27.1, 27.1, 29.1, 29.3, 29.4, 29.7, 111.1, 111.9, 113.7, 117.2, 118.7, 119.2, 119.3, 121.4, 123.4, 124.5, 
132.3, 132.9, 134.2, 135.1, 135.4, 136.7, 138.2, 138.9, 139.7,  141.6, 143.3, 144.3, 146.3, 149.5, 151.8, 
155.2, 172.7. MS [ESI, m/z]: 349 [M+H]. Anal. Calcd for C18H16N6S: C, 62.05; H, 4.63; N, 24.12. Found: 
C, 61.89; H, 4.51; N, 24.33. 
 
4.1.1.23 2-(1-(2-(5,6-Dimethylthieno[2,3-d]pyrimidin-4-yl)hydrazono)ethyl)benzene-1,4-diol (1c) 
Obtained in 71% yield as a yellow solid. M.p. > 300 °C. Two sets of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : (first set) 2.36 (s, 3H), 2.47 (s, 3H), 2.49 (s, 3H), 6.73-6.77 (m, 
2H), 6.97-7.02 (m, 1H), 7.74 (s, 1H, H-2), 8.87 (broad s, 1H), 11.36 (broad s, 1H), 11.71 (broad s, 1H). 
1H-NMR (DMSO-d6), : (second set) 2.47 (s, 3H), 2.49 (s, 3H), 2.61 (s, 3H), 6.73-6.77 (m, 2H), 6.97-
7.02 (m, 1H), 8.52 (s, 1H), 8.87 (broad s, 1H), 9.51 (broad s, 1H), 12.60 (broad s, 1H). 13C-NMR (DMSO-
d6), : (first and second set) 12.8, 14.1, 15.0, 112.5, 114.2, 116.9, 118.1, 121.1, 128.8, 129.5, 143.8, 
144.6, 149.2, 150.8, 155.1, 163.0. MS [ESI, m/z]: 329 [M+H]. Anal. Calcd for  C16H16N4O2S: C, 58.52; 
H, 4.91; N, 17.06. Found: C, 58.46; H, 4.89; N, 17.25. 
 
4.1.1.24 2-(1-(2-(5,6-Dimethylthieno[2,3-d]pyrimidin-4-yl)hydrazono)ethyl)phenol (11c) 
Obtained in 54% yield as a pale yellow solid. M.p. 222-226 °C. Two sets of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : (first set) 2.36 (s, 3H), 2.49 (s, 3H), 2.53 (s, 3H), 6.89-6.93 (m, 
2H), 7.27-7.30 (m, 1H), 7.61 (d, J= 7.5 Hz, 1H), 7.75 (s, 1H), 11.38 (broad s, 1H), 12.49 (broad s, 1H).  
1H-NMR (DMSO-d6), : (second set) 2.47 (s, 3H), 2.53 (s, 3H), 2.61 (s, 3H), 6.89-6.93 (m, 2H), 7.27-
7.30 (m, 1H), 7.64-7.67 (m, 1H), 8.54 (s, 1H), 9.54 (broad s, 1H), 13.37 (broad s, 1H). 13C-NMR (DMSO-
d6), : (first and second set) 12.8, 13.0, 13.2, 13.5, 14.1, 14.9, 116.5, 117.2, 118.5, 118.6, 119.4, 120.1, 
121.0, 124.2, 128.0, 128.7, 128.8, 129.5, 130.6, 143.8, 145.4, 152.5, 153.9, 155.3, 155.8, 158.1, 158.4, 
163.3, 165.1. MS [ESI, m/z]: 313 [M+H]. Anal. Calcd for C16H16N4OS: C, 61.52; H, 5.16; N, 17.93. 
Found: C, 61.67; H, 4.99; N, 18.01. 
 
4.1.1.25 2-(1-(2-(6-Ethyl-5-methylthieno[2,3-d]pyrimidin-4-yl)hydrazono)ethyl) benzene-1,4-diol (1d) 
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Obtained in 53% yield as a yellow soild. M.p. 235-237 °C. Two sets of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : (first set) 1.22 (t, J= 7.4 Hz, 3H), 2.46 (s, 3H), 2.52 (s, 3H), 2.78 
(q, J= 7.4 Hz, 2H), 6.73-6.76 (m, 2H), 6.97-6.99 (m, 1H), 7.74 (s, 1H), 8.87 (broad s, 1H), 11.36 (broad 
s, 1H), 11.70 (broad s, 1H). 1H-NMR (DMSO-d6), : (second set) 1.26 (t, J= 7.4 Hz, 3H), 2.45 (s, 3H), 
2.63 (s, 3H), 2.89 (q, J= 7.4 Hz, 2H), 6.73-6.76 (m, 2H), 7.00-7.02 (m, 1H), 8.53 (s, 1H), 8.87 (broad s, 
1H), 9.53 (broad s, 1H), 12.60 (broad s, 1H). 13C-NMR (DMSO-d6), : (first and second set) 14.0, 15.0, 
15.3, 20.6, 114.2, 116.9, 118.0, 120.7, 121.1, 127.9, 137.0, 143.8, 144.7, 149.2, 150.8, 155.2, 163.0. MS 
[ESI, m/z]: 343 [M+H]. Anal. Calcd for C17H18N4O2S: C, 59.63; H, 5.30; N, 16.35. Found: C, 59.69; H, 
5.31; N, 16.51. 
 
4.1.1.26 2-[1-(Thieno[2,3-d]pyrimidin-4-yl-hydrazono)-ethyl]-benzene-1,4-diol (1f) 
Obtained in 81% yield as a yellow solid. M.p. 267-269 °C. Single set of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : 2.47 (s, 3H), 6.75-6.76 (m, 2H), 6.98-7.00 (m, 1H), 7.73 (d, J= 
5.8 Hz, 1H), 7.93 (d, J= 5.8 Hz, 1H), 7.93 (broad s, 1H), 8.90 (s, 1H), 10.74 (broad s, 1H), 12.10 (broad 
s, 1H). 13C-NMR (DMSO-d6), : 14.3, 113.4, 115.3, 117.5, 118.3, 120.8, 121.2, 123.9, 149.2, 150.6, 
152.9, 153.3, 154.4, 167.4. MS [ESI, m/z]: 301 [M+H]. Anal. Calcd for C14H12N4O2S: C, 55.99; H, 4.03; 
N, 18.65. Found: C, 56.13; H, 4.33; N, 18.71. 
 
4.1.1.27 2-[1-(Thieno[2,3-d]pyrimidin-4-yl-hydrazono)-ethyl]-phenol (11f) 
Obtained in 61% yield as pale yellow crystals. M.p. 178-180 °C. Single set of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : 2.54 (s, 3H), 6.89-6.94 (m, 2H), 7.27-7.31 (m, 1H), 7.61 (dd, J1= 
7.9 Hz, J2= 1.3 Hz, 1H), 7.72-7.76 (m, 1H), 7.91-7.95 (m, 1H), 8.60 (s, 1H), 10.79 (broad s, 1H), 12.93 
(broad s, 1H). 13C-NMR (DMSO-d6), : 14.2, 115.4, 117.0, 118.5, 120.1, 120.5, 124.0, 128.2, 130.7, 
153.3, 154.2, 154.7, 158.0, 167.3. MS [ESI, m/z]: 285 [M+H]. Anal. Calcd for C14H12N4OS: C, 59.14; 
H, 4.25; N, 19.70. Found: C, 58.91; H, 5.51; N, 19.64. 
 
4.1.1.28 4-(2-(1-(Pyrazin-2-yl)ethylidene)hydrazinyl)thieno[2,3-d]pyrimidine (16f) 
Obtained in 96% yield a white solid. M.p. 239-243 °C. Two sets of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : (first set) 2.52 (s, 3H), 7.79 (d, J= 5.9 Hz, 1H), 8.08 (d, J= 5.9 Hz, 
1H), 8.60 (s, 1H), 8.64-8.67 (m, 1H), 8.69-8.70 (m, 1H), 9.26 (s, 1H), 11.21 (broad s, 1H). 1H-NMR 
(DMSO-d6), : (second set) 2.52 (s, 3H), 7.47 (d, J= 5.3 Hz, 1H), 7.62 (d, J= 5.3 Hz, 1H), 7.98-8.00 (m, 
1H), 8.60 (s, 1H), 8.64-8.67 (m, 1H), 9.81 (s, 1H), 12.06 (broad s, 1H). 13C-NMR (DMSO-d6), : (first 
and second set) 11.9, 12.3, 115.0, 121.1, 122.3, 124.2, 141.8, 142.1, 143.3, 143.5, 143.6, 143.8, 144.6, 
144.7, 148.3, 150.7, 152.6, 156.0. MS [ESI, m/z]: 271 [M+H]. Anal. Calcd for C12H10N6S: C, 53.32; H, 
3.73; N, 31.09. Found: C, 53.27; H, 3.91; N, 31.05. 
 
4.1.1.29 2-(1-(2-(Benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)hydrazono)ethyl)benzene-1,4-diol (1g) 
Obtained as a yellow solid in 73% yield. M.p. 246-249 °C. Two sets of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : (first set) 2.62 (s, 3H), 6.77-6.79 (m, 2H), 7.04-7.07 (m, 1H), 7.50-
7.52 (m, 1H), 7.57-7.63 (m, 1H), 8.03-8.08 (m, 2H), 8.74 (d, J= 7.9 Hz, 1H), 8.91 (broad s, 1H), 11.66 
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(broad s, 1H), 12.06 (broad s, 1H). 1H-NMR (DMSO-d6), : (second set) 2.62 (s, 3H), 6.77-6.79 (m, 2H), 
7.04-7.07 (m, 1H), 7.57-7.63 (m, 1H), 7.66-7.71 (m, 1H), 8.15-8.19 (m, 1H), 8.33-8.37 (m, 1H), 8.74 (d, 
J= 7.9 Hz, 1H), 8.91 (broad s, 1H), 10.42 (broad s, 1H), 12.70 (broad s, 1H). 13C-NMR (DMSO-d6), : 
(first and second set) 15.2, 114.1, 114.3, 117.0, 118.3, 121.1, 122.7, 125.2, 125.6, 125.7, 133.2, 135.1, 
145.0, 147.0, 149.3, 150.8, 160.8, 163.3. MS [ESI, m/z]: 351 [M+H]. Anal. Calcd for C18H14N4O2S: C, 
61.70; H, 4.03; N, 15.99. Found: C, 61.58; H, 4.29; N, 15.87. 
 
4.1.1.30 2-(1-(2-(Benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)hydrazono)ethyl)phenol (11g) 
Obtained in 81% yield as a yellow solid. M.p. 197-199 °C. Two sets of signals observed. 1H-NMR 
(DMSO-d6), : (first set) 2.66 (s, 3H), 6.92-6.97 (m, 2H), 7.30-7.34 (m, 1H), 7.50-7.52 (m, 1H), 7.58-
7.60 (m, 1H), 7.65-7.70 (m, 1H), 8.04-8.09 (m, 2H), 8.73-8.79 (m, 1H), 12.04 (broad s, 1H), 12.39 (broad 
s, 1H). 1H-NMR (DMSO-d6), : (second set) 2.66 (s, 3H), 6.92-6.97 (m, 2H), 7.30-7.34 (m, 1H), 7.58-
7.60 (m, 1H), 7.65-7.70 (m, 2H), 8.15-8.19 (m, 1H), 8.34-8.38 (m, 1H), 8.73-8.79 (m, 1H), 10.46 (broad 
s, 1H), 13.46 (broad s, 1H). 13C-NMR (DMSO-d6), : (first and second set) 15.1, 114.1, 116.6, 118.7, 
121.1, 122.7, 125.2, 125.6, 125.7, 128.9, 130.8, 133.2, 135.2, 145.1, 146.9, 158.1, 160.9, 163.4. MS [ESI, 
m/z]: 335 [M+H]. Anal. Calcd for C18H14N4OS: C, 64.65; H, 4.22; N, 16.75. Found: C, 64.74; H, 4.10; 
N, 16.89. 
 
4.1.1.31 4-(2-(1-(Pyrazin-2-yl)ethylidene)hydrazinyl)benzo[4,5]thieno[2,3-d]pyrimidine (16g) 
Obtained as a yellow solid in 73% yield. M.p. 218-221 °C. Single set of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : 2.62 (s, 3H), 7.50-7.54 (m, 1H), 7.58-7.62 (m, 1H), 8.08 (d, J= 
7.9 Hz, 1H), 8.15 (d, J= 3.7 Hz), 8.61 (s, 1H), 8.65-8.66 (m, 1H), 8.78 (d, J= 7.9 Hz), 9.87 (d, J= 1.4 Hz, 
1H), 12.44 (broad s, 1H). 13C-NMR (DMSO-d6), : 12.8, 114.4, 122.7, 125.5, 125.6, 125.8, 133.1, 135.2, 
143.2, 143.4, 143.6, 146.6, 148.2, 151.1, 157.5, 161.8. MS [ESI, m/z]: 321 [M+H]. Anal. Calcd for 
C16H12N6OS: C, 59.98; H, 3.78; N, 26.23. Found: C, 59.85; H, 3.66; N, 26.31. 
 
4.1.1.32 4-(2-(1-(1H-Benzo[d]imidazol-2-yl)ethylidene)hydrazinyl)benzo[4,5]thieno[2,3-d] pyrimidine 
(20g) 
Obtained in 62% yield as a yellow solid. M.p. charring > 250 °C. Two sets of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : (first set) 2.67 (s, 3H), 7.22-7.32 (m, 2H), 7.52-7.55 (m, 1H), 7.61-
7.72 (m, 3H), 8.10 (d, J= 7.9 Hz, 1H), 8.36 (s, 1H), 8.80 (d, J= 7.9 Hz, 1H), 12.60 (broad s, 1H), 12.68 
(broad s, 1H). 1H-NMR (DMSO-d6), : (second set) 2.63 (s, 3H), 7.45-7.48 (m, 2H), 7.61-7.72 (m, 2H), 
7.91-8.00 (m, 2H), 8.22 (d, J= 7.9 Hz, 1H), 8.75 (s, 1H), 9.31 (d, J= 7.9 Hz, 1H), 13.21 (broad s, 1H), 
13.49 (broad s, 1H). 13C-NMR (DMSO-d6), : (first and second set) 13.3, 114.3, 121.5, 123.2, 124.8, 
125.7, 125.8, 125.9, 126.9, 130.4, 133.1, 134.8, 135.2, 146.3, 148.6, 150.4, 151.6, 155.2, 161.8. MS [ESI, 
m/z]: 359 [M+H]. Anal. Calcd for C19H14N6S: C, 63.67; H, 3.94; N, 23.45. Found: C, 63.61; H, 3.79; N, 
23.56. 
 
4.1.1.33 2-(1-(2-(2-Methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl) hydrazono)ethyl) 
phenol (11h) 
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Obtained in 86% yield as a pale yellow solid. M.p. 257-260 °C. Two sets of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : (first set) 1.77-1.82 (m, 4H), 2.33 (s, 3H), 2.49 (s, 3H), 2.72-2.75 
(m, 2H), 2.97-3.01 (m, 2H), 6.88-6.96 (m, 2H), 7.26-7.31 (m, 1H), 7.58-7.65 (m, 1H), 10.96 (broad s, 
1H), 12.73 (broad s, 1H). 1H-NMR (DMSO-d6), : (second set) 1.85-1.89 (m, 4H), 2.49 (s, 3H), 2.56 (s, 
3H), 2.79-2.84 (m, 2H), 3.12-3.16 (m, 2H), 6.88-6.96 (m, 2H), 7.26-7.31 (m, 1H), 7.58-7.65 (m, 1H), 
9.32 (broad s, 1H), 13.35 (broad s, 1H). 13C-NMR (DMSO-d6), : (first and second set) 12.8, 14.6, 21.2, 
22.0, 22.1, 22.2, 22.4, 24.6, 24.9, 25.5, 26.4, 113.6, 116.5, 117.3, 117.4, 118.4, 118.5, 119.6, 121.0, 
126.1, 127.9, 128.5, 130.5, 130.7, 131.3, 132.4, 145.9, 152.8, 153.7, 154.5, 157.0, 158.4, 161.4, 162.6, 
166.6. MS [ESI, m/z]: 353 [M+H]. Anal. Calcd for C19H20N4OS: C, 64.75; H, 5.72; N, 15.90. Found: C, 
64.83; H, 5.76, N, 16.03. 
 
4.1.1.34 2-Methyl-4-(2-(1-(pyrazin-2-yl)ethylidene)hydrazinyl)-5,6,7,8-tetrahydrobenzo [4,5]thieno 
[2,3-d]pyrimidine (16h) 
Obtained in 59% yield as a yellow solid. M.p. 189-191 °C. Single set of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : 1.76-1.82 (m, 4H), 2.44 (s, 3H), 2.46 (s, 3H), 2.72-2.74 (m, 2H), 
3.00-3.03 (m, 2H), 8.58 (d, J= 2.6 Hz, 1H), 8.61 (dd, J1= 2.6 Hz, J2= 1.4 Hz, 1H), 9.82 (d, J= 1.4 Hz, 
1H), 11.18 (broad s, 1H). 13C-NMR (DMSO-d6), : 12.8, 21.5, 22.1, 22.3, 24.6, 26.4, 117.7, 130.6, 131.5, 
143.1, 143.4, 143.6, 148.9, 151.2, 152.7, 157.0, 158.2. MS [ESI, m/z]: 339 [M+H]. Anal. Calcd for 
C17H18N6S: C, 60.33; H, 5.36; N, 24.83. Found: C, 60.42; H, 5.28; N, 24.87. 
 
4.1.1.35 2-(1-(2-(6-Chloro-5-methylthieno[2,3-d]pyrimidin-4-yl)hydrazono)ethyl)phenol (11i) 
Obtained in 77% yield as a light grey solid. M.p. 220-223 °C. Two sets of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : (first set) 2.51 (s, 3H), 2.54 (s, 3H), 6.89-6.94 (m, 2H), 7.29-7.31 
(m, 1H), 7.60-7.67 (m, 1H), 7.82 (s, 1H), 11.61 (broad s, 1H), 12.29 (broad s, 1H). 1H-NMR (DMSO-
d6), : (second set) 2.54 (s, 3H), 2.69 (s, 3H), 6.89-6.94 (m, 2H), 7.29-7.31 (m, 1H), 7.60-7.67 (m, 1H), 
8.63 (s, 1H), 9.68 (broad s, 1H), 13.26 (broad s, 1H). 13C-NMR (DMSO-d6), : (first and second set) 
14.3, 15.1, 116.5, 118.7, 119.2, 120.7, 121.0, 128.8, 130.9, 144.5, 145.5, 155.9, 158.1, 164.0. MS [ESI, 
m/z]: 332.9, 334.9 [M+H]. Anal. Calcd for C15H13ClN4OS: C, 54.13; H, 3.94; N, 16.83. Found: C, 53.96; 
H, 4.17; N, 16.77. 
 
4.1.1.36 6-Chloro-5-methyl-4-(2-(1-(pyrazin-2-yl)ethylidene)hydrazinyl)thieno[2,3-d]pyrimidine (16i) 
Obtained in 64% yield as a yellow solid. M.p. 235-237 °C. Single set of signals observed in NMR 
experiments. 1H-NMR (DMSO-d6), : 2.48 (s, 3H), 2.58 (s, 3H), 7.95 (s, 1H), 8.61 (d, J= 2.4 Hz, 1H), 
8.64-8.65 (m, 1H), 9.79 (s, 1H), 12.09 (broad s, 1H). 13C-NMR (DMSO-d6), : 12.7, 14.2, 115.7, 120.0, 
143.2, 143.3, 143.7, 144.9, 147.4, 148.7, 150.8, 155.0, 164.9. MS [ESI, m/z]: 318.9, 320.9 [M+H]. Anal. 
Calcd for C13H11ClN6S: C, 48.98; H, 3.48; N, 26.36. Found: C, 48.94; H, 3.76, N, 26.32. 
 
4.1.2 General method for the preparation of (thieno[2,3-d]pyrimidin-4-yl)-hydrazides 25-36 
The aryl carboxylic acid (1.1 eq.) and TBTU (1.2) were suspended in anhydrous THF (11 mL/mmol eq.) 
at r.t. under N2 atmosphere. DiPEA (2.4 eq.) was then added dropwise to the reaction mixture, followed 
 23 
by the different (thieno[2,3-d]pyrimidin-4-yl)-hydrazine (8a-d or f-i) (1 eq.) dissolved in anhydrous THF 
(11 mL/mmol eq.). The mixture was stirred at r.t. for 4 h, then concentrated under vacuum. The residue 
was dissolved in EtOAc (30 mL/mmol eq.), washed with water (30 mL/mmol eq.), saturated NaHCO3 
solution (30 mL/mmol eq.), and finally with brine (30 mL/mmol eq.). The organic phase was 
concentrated under vacuum after drying over MgSO4. The crude residue was purified by re-
crystallisation or flash column chromatography. 
 
4.1.2.1 2,5-Dihydroxy-benzoic acid N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-
hydrazide (25a)  
Purified by crystallisation from EtOH. Obtained in 28% yield as a light grey solid. M.p. 261-263 °C. 
1H-NMR (DMSO-d6), : 1.81-1.91 (m, 4H), 2.80-2.86 (m, 2H), 2.99-3.08 (m, 2H), 6.82 (d, J= 8.7 Hz, 
1H), 6.91 (dd, J1= 8.7 Hz, J2= 1.6 Hz, 1H), 7.37 (d, J= 1.6 Hz, 1H), 8.36 (s, 1H), 8.77 (broad s, 1H), 9.09 
(broad s, 1H), 10.77 (bs 1H), 11.17 (broad s, 1H).
 
13C-NMR (DMSO-d6), : 21.9, 22.1, 24.9, 25.6, 114.0, 
115.1, 115.4, 117.8, 121.4, 126.4, 132.9, 149.6, 151.1, 152.3, 156.4, 165.2, 166.4. MS [ESI, m/z]: 357 
[M+H]. Anal. Calcd for C17H16N4O3S: C, 57.29; H, 4.52; N, 15.72. Found: C, 57.12; H, 4.73; N, 15.66. 
 
4.1.2.2 2-Hydroxy-benzoic acid N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-
hydrazide (26a) [45]  
Purified by crystallisation from EtOH/H2O. Obtained in 35% yield as a light orange solid. M.p. 327-329 
°C. 1H-NMR (DMSO-d6), : 1.84-1.88 (m, 4H), 2.79-2.88 (m, 2H), 2.98-3.08 (m, 2H), 6.94-7.01 (m, 
2H), 7.74 (t, J= 7.7 Hz, 1H), 8.00 (d, J= 7.7 Hz, 1H), 8.37 (s, 1H), 8.79 (broad s, 1H), 10.85 (broad s, 
1H), 10.77 (bs 1H), 11.99 (broad s, 1H). 13C-NMR (DMSO-d6), : 21.9, 22.1, 24.9, 25.6, 114.7, 117.3, 
119.0, 126.4, 128.3, 133.0, 134.0, 149.4, 151.2, 152.3, 156.6, 159.2. MS [ESI, m/z]: 341 [M+H]. Anal. 
Calcd for C17H16N4O2S: C, 59.98; H, 4.74; N, 16.46. Found: C, 60.12; H, 4.55; N, 16.53. 
 
4.1.2.3 3-Hydroxy-N'-(5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)benzo hydrazide (27a)  
Purified by crystallisation from EtOH. Obtained in 29% yield as a white solid. M.p. 241-243 °C. 1H-
NMR (DMSO-d6), : 1.83-1.87 (m, 4H), 2.81-2.84 (m, 2H), 3.01-3.04 (m, 2H), 6.96-6.99 (m, 1H), 7.29-
7.33 (m, 1H), 7.34-7.35 (m, 1H), 7.40 (dt, J1= 7.7 Hz, J2= 1.2 Hz, 1H), 8.34 (s, 1H), 8.58 (broad s, 1H), 
9.70 (broad s, 1H), 10.48 (broad s, 1H). 13C-NMR (DMSO-d6), : 21.9, 22.1, 24.9, 25.7, 114.5, 115.1, 
117.9, 118.6, 126.4, 129.4, 132.7, 134.1, 152.4, 157.3, 157.5, 165.3, 165.9. MS [ESI, m/z]: 341 [M+H]. 
Anal. Calcd for C17H16N4O2S: C, 59.98; H, 4.74; N, 16.46. Found: C, 59.79; H, 4.55; N, 16.67. 
 
4.1.2.4 Pyrazine-2-carboxylic acid N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-
hydrazide (28a)  
Purified by crystallisation from DCM/n-hexane. Obtained in 29% yield as a pale yellow solid. M.p. 200-
202 °C. 1H-NMR (CDCl3), : 1.90-2.00 (m, 4H), 2.84-2.87 (m, 2H), 3.06-3.10 (m, 2H), 8.19 (broad s, 
1H), 8.51 (s, 1H), 8.61-8.62 (m, 1H), 8.81 (d, J= 2.4 Hz, 1H), 9.39 (d, J= 1.3 Hz, 1H), 10.68 (broad s, 
1H). 13C-NMR (CDCl3), : 22.4, 22.4, 25.4, 26.0, 115.8, 125.2, 135.5, 143.0, 143.2, 144.2, 147.9, 152.2, 
154.3, 159.2, 166.3. MS [ESI, m/z]: 327 [M+H]. Anal. Calcd for C15H14N6OS: C, 55.20; H, 4.32; N, 
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25.75. Found: C, 55.13; H, 4.22; N, 25.83. 
 
4.1.2.5 Pyridine-2-carboxylic acid N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-
hydrazide (29a) 
Purified by crystallisation from EtOH. Obtained in 67% yield as a light grey solid. M.p. 232-234 °C. 
1H-NMR (CDCl3), : 1.89-2.00 (m, 4H), 2.83-2.87 (m, 2H), 3.07-3.11 (m, 2H), 7.47-7.51 (m, 1H), 7.89 
(td, J1= 7.7 Hz, J2= 1.6 Hz, 1H), 8.15-8.20 (m, 2H), 8.52 (s, 1H), 8.65 (d, J= 4.7 Hz, 1H), 10.77 (broad 
s, 1H).
 
13C-NMR (CDCl3), : 22.4, 22.5, 25.4, 26.1, 115.7, 122.3, 125.3, 126.7, 135.1, 137.4, 148.3, 
148.7, 152.4, 154.5, 160.5, 166.2. MS [ESI, m/z]: 326 (M+H). Anal. Calcd for C16H15N5OS: C, 59.06; 
H, 4.65; N, 21.51. Found: C, 58.99; H, 4.61; N, 21.51. 
 
4.1.2.6 N'-(5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)nicotinohydrazide (30a) 
Purified by crystallisation from EtOH/H2O. Obtained in 23% yield as a pale yellow solid. M.p. 137-140 
°C. 1H-NMR (DMSO-d6), : 1.84-1.89 (m, 4H), 2.81-2.85 (m, 2H), 3.02-3.06 (m, 2H), 7.58 (dd, J1= 8.4 
Hz, J2= 4.8 Hz), 8.28-8.31 (m, 1H), 8.36 (s, 1H), 8.69- 8.71 (m, 1H), 8.78-8.80 (m, 1H), 9.12 (broad s, 
1H), 10.80 (broad s, 1H). 13C-NMR (DMSO-d6), : 21.9, 22.1, 24.9, 25.7, 115.2, 123.6, 126.4, 128.3, 
132.9, 135.2, 148.4, 152.4, 157.2, 164.5, 165.4. MS [ESI, m/z]: 326 [M+H]. Anal. Calcd for C16H15N5OS: 
C, 59.06; H, 4.65; N, 21.51. Found: C, 59.02; H, 4.79; N, 21.60. 
 
4.1.2.7 N'-(5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-1H-indole-2-carbo hydrazide 
(31a)  
Purified by crystallisation from EtOH. Obtained in 36% yield as a plae yellow solid. M.p. 232-235 °C. 
1H-NMR (DMSO-d6), : 1.83-1.89 (m, 4H), 2.81-2.85 (m, 2H), 3.03-3.08 (m, 2H), 7.06-7.09 (m, 1H), 
7.20-7.24 (m, 1H), 7.34 (s, 1H), 7.47 (d, J= 8.2 Hz, 1H), 7.68 (d, J= 8.0 Hz, 1H), 8.35 (s, 1H), 8.70 (broad 
s, 1H), 10.58 (broad s, 1H), 11.69 (broad s, 1H).
 
13C-NMR (DMSO-d6), : 22.0, 22.1, 24.9, 25.8, 103.4, 
112.3, 115.1, 119.8, 121.6, 123.6, 126.4, 127.0, 129.7, 132.7, 136.6, 152.4, 157.5, 160.9, 165.3. MS [ESI, 
m/z]: 364 [M+H]. Anal. Calcd for C19H17N5OS: C, 62.79; H, 4.71; N, 19.27. Found: C, 62.87; H, 4.56; 
N, 19.36. 
 
4.1.2.8 N'-(5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-1H-benzo[d] imidazole-2-
carbohydrazide (32a)  
Purified by crystallisation from EtOH. Obtained in 26% yield as a yellow solid. M.p. >300 °C. 1H-NMR 
(DMSO-d6), : 1.83-1.86 (m, 4H), 2.80-2.84 (m, 2H), 3.00-3.04 (m, 2H), 7.31-7.37 (m, 2H), 7.55-7.61 
(m, 1H), 7.76-7.82 (m, 1H), 8.34 (s, 1H), 8.79 (broad s, 1H), 10.89 (broad s, 1H), 13.40 (broad s, 1H). 
13C-NMR (DMSO-d6), : 21.9, 22.1, 24.9, 25.7, 112.5, 115.2, 120.0, 122.7, 124.3, 126.4, 132.8, 134.3, 
142.5, 144.3, 152.3, 156.9, 158.4, 165.3. MS [ESI, m/z]: 365 [M+H]. Anal. Calcd for C18H16N6OS: C, 
59.32; H, 4.43; N, 23.06. Found: C, 59.51; H, 4.27; N, 23.15. 
 
4.1.2.9 N'-(5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)quinoline-2-carbohydrazide (33a) 
Purified by crystallisation from EtOH. Obtained in 68% yield as a white solid. M.p. 261-263 °C. 
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1H-NMR (DMSO-d6), : 1.85-1.89 (m, 4H), 2.82-2.86 (m, 2H), 3.04-3.08 (m, 2H), 7.75-7.78 (m, 1H), 
7.90-7.94 (m, 1H), 8.12 (d, J= 8.1 Hz, 1H), 8.17 (d, J= 8.4 Hz, 1H), 8.20 (d, J= 8.4 Hz, 1H), 8.34 (s, 1H), 
8.61 (d, J= 8.4 Hz, 1H), 8.76 (broad s, 1H), 10.84 (broad s, 1H).
 
13C-NMR (DMSO-d6), : 21.9, 22.1, 
24.9, 25.7, 115.2, 118.8, 122.3, 126.5, 128.1, 128.3, 128.9, 129.3, 130.6, 132.8, 137.9, 146.0, 149.7, 
152.4, 158.6, 164.2. MS [ESI, m/z]: 376 [M+H]. Anal. Calcd for C20H17N5OS: C, 63.98; H, 4.56; N, 
18.65. Found: C, 64.11; H, 4.77; N, 18.82. 
 
4.1.2.10 N'-(5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carbohydrazide 
(34a) 
Purified by crystallisation from MeOH. Obtained in 65% yield as a pale yellow solid. M.p. charring > 
300 °C. 1H-NMR (DMSO-d6), : 1.83-1.87 (m, 4H), 2.80-2.84 (m, 2H), 3.00-3.04 (m, 2H), 6.14-6.17 (m, 
1H), 6.93-6.95 (m, 1H), 6.98-7.00 (m, 1H), 8.32 (s, 1H), 8.52 (broad s, 1H), 10.08 (broad s, 1H), 11.56 
(broad s, 1H). 13C-NMR (DMSO-d6), : 22.0, 22.1, 24.9, 25.8, 108.7, 110.9, 115.0, 122.0, 124.3, 126.4, 
132.6, 152.4, 157.4, 160.4, 165.2. MS [ESI, m/z]: 314 [M+H]. Anal. Calcd for C15H15N5OS: C, 57.49; 
H, 4.82; N, 22.35. Found: C, 57.62; H, 5.01; N, 22.46. 
 
4.1.2.11 N'-(5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)furan-2-carbo hydrazide (35a) 
Purified by crystallisation from MeOH. Obtained in 35% yield as white crystals. M.p. 216-219 °C. 1H-
NMR (DMSO-d6), : 1.83-1.86 (m, 4H), 2.80-2.84 (m, 2H), 2.99-3.03 (m, 2H), 6.69 (dd, J1= 3.5 Hz, J2= 
1.7 Hz, 1H), 7.29 (dd, J1= 3.5 Hz, J2= 0.4 Hz, 1H), 7.92-7.93 (m, 1H), 8.34 (s, 1H), 8.59 (broad s, 1H), 
10.45 (broad s, 1H). 13C-NMR (DMSO-d6), : 21.9, 22.1, 24.9, 25.7, 111.8, 114.4, 115.1, 126.4, 132.8, 
145.6, 146.4, 152.3, 157.3, 157.5, 165.3. MS [ESI, m/z]: 315 [M+H]. Anal. Calcd for C15H14N4O2S: C, 
57.31; H, 4.49; N, 17.82. Found: C, 57.09; H, 4.73; N, 4.41. 
 
4.1.2.12 N'-(5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)thiophene-2-carbo hydrazide 
(36a)  
Purified by crystallisation from MeOH. Obtained in 15% yield as a white solid. M.p. 219-221 °C. 1H-
NMR (DMSO-d6), : 1.82-1.89 (m, 4H), 2.80-2.86 (m, 2H), 2.99-3.05 (m, 2H), 7.21-7.25 (m, 1H), 7.84-
7.85 (m, 1H), 7.94-7.98 (m, 1H), 8.35 (s, 1H), 8.64 (broad s, 1H), 10.60 (broad s, 1H).
 
13C-NMR (DMSO-
d6), : 21.9, 22.1, 24.9, 25.7, 115.1, 126.4, 128.1, 128.9, 131.4, 132.8, 137.6, 152.4, 157.3, 160.9, 165.4. 
MS [ESI, m/z]: 331 [M+H]. Anal. Calcd for C15H14N4OS2: C, 54.52; H, 4.27; N, 19.96. Found: C, 54.48; 
H, 4.49; N, 19.93. 
 
4.1.2.13 N'-(6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)-2,5-dihydroxy 
benzohydrazide (25b)  
Purified by crystallisation from EtOH. Obtained in 26% yield as a light grey solid. M.p. charring > 248 
°C. 1H-NMR (DMSO-d6), : 2.42-2.48 (m, 2H), 2.99 (t, J=7.1 Hz, 2H), 3.12 (, J=6.9 Hz, 2H), 6.82 (d, 
J= 8.8 Hz, 1H), 6.92 (dd, J1= 8.8 Hz, J2= 2.8 Hz, 1H), 7.37 (d, J= 2.8 Hz, 1H), 8.35 (s, 1H), 8.98 (broad 
s, 1H), 9.09 (broad s, 1H), 10.66 (broad s 1H), 11.18 (broad s, 1H). 13C-NMR (DMSO-d6), : 27.4, 29.2, 
111.9, 113.8, 115.2, 117.8, 121.6, 135.3, 138.5, 149.5, 151.4, 152.2, 156.4, 167.3, 170.9. MS [ESI, m/z]: 
 26 
343 [M+H].  Anal. Calcd for C16H14N4O3S: C, 56.13; H, 4.12; N, 16.36. Found: C, 56.07; H, 3.99; N, 
16.45. 
 
4.1.2.14 N'-(6,7-Dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)-2-hydroxybenzo hydrazide 
(26b)  
Purified by flash column chromatography eluting with n-hexane-EtOAc 100:0 v/v increasing to n-
hexane-EtOAc 0:100 v/v. Obtained in 30% yield as a white solid. TLC (EtOAc, Rf: 0.70). M.p. charring 
> 230 °C. 1H-NMR (DMSO-d6), : 2.43-2.49 (m, 2H), 3.00 (t, J=7.1 Hz, 2H), 3.13 (, J=7.1 Hz, 2H), 6.96-
7.00 (m, 2H), 7.46-7.50 (m, 1H), 7.99 (dd, J1= 7.9 Hz, J2= 1.2 Hz, 1H), 8.36 (s, 1H), 9.01 (broad s, 1H), 
10.79 (bs 1H), 11.98 (broad s, 1H). 13C-NMR (DMSO-d6), : 27.4, 29.2, 29.2, 111.9, 114.5, 117.4, 119.0, 
128.2, 134.1, 135.3, 138.6, 152.3, 156.5, 159.4, 168.1, 171.0. MS [ESI, m/z]: 327 [M+H]. Anal. Calcd 
for C16H14N4O2S: C, 58.88; H, 4.32; N, 17.17. Found: C, 58.75; H, 4.11; N, 17.25. 
 
4.1.2.15 N'-(6,7-Dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)pyrazine-2-carbo hydrazide 
(28b)  
Purified by crystallisation from EtOH. Obtained in 15% yield as a light brown solid. M.p. 174-178 °C.  
1H-NMR (DMSO-d6), : 2.41-2.47 (m, 2H), 2.98 (t, J= 7.1 Hz, 2H), 3.12 (, J= 6.7 Hz, 2H), 8.33 (s, 1H), 
8.82-8.83 (m, 1H), 8.95 (d, J= 2.4 Hz, 1H), 9.00 (broad s, 1H), 9.22 (d, J= 1.2 Hz, 1H), 10.93 (bs 1H).
 
13C-NMR (DMSO-d6), : 27.4, 29.2, 29.3, 111.9, 135.3, 138.4, 143.6, 143.6, 144.3, 148.0, 152.2, 156.6, 
162.5, 169.9. MS [ESI, m/z]: 313 [M+H]. Anal. Calcd for C14H12N6OS: C, 53.83; H, 3.87; N, 26.91. 
Found: C, 53.76; H, 3.71; N, 27.13.
 
 
4.1.2.16 N'-(6,7-Dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)picolinohydrazide (29b) 
Purified by crystallisation from EtOH. Obtained as a grey solid in 30% yield. M.p. 219-222 °C. 1H-NMR 
(DMSO-d6), : 2.40-2.46 (m, 2H), 2.98 (t, J= 7.1 Hz, 2H), 3.12 (, J= 6.9 Hz, 2H), 7.66-7.69 (m, 1H), 
8.02-8.05 (m, 2H), 8.31 (s, 1H), 8.72-8.74 (m, 1H), 8.96 (broad s, 1H), 10.72 (bs 1H). 13C-NMR (DMSO-
d6), : 27.4, 29.2, 29.3, 111.9, 114.8, 122.3, 126.9, 135.4, 137.8, 138.2, 148.6, 149.3, 152.2, 156.2, 169.7. 
MS [ESI, m/z]: 312 [M+H]. Anal. Calcd for C15H13N5OS: C, 57.86; H, 4.21; N, 22.49. Found: C, 57.99; 
H, 4.30; N, 22.66. 
 
4.1.2.17 N'-(6,7-Dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)-1H-benzo[d] imidazole-2-
carbohydrazide (32b)  
Purified by crystallisation from EtOH. Obtained in 47% yield as a white solid. M.p. 230-234°C. 1H-NMR 
(DMSO-d6), : 2.40-2.47 (m, 2H), 2.96-3.00 (m, 2H), 3.11-3.14 (, m, 2H), 7.30-7.38 (m, 2H), 7.56-7.60 
(m, 1H), 7.78-7.82 (m, 1H), 8.33 (s, 1H), 9.04 (broad s, 1H), 10.96 (bs 1H), 13.40 (broad s, 1H). 13C-
NMR (DMSO-d6), : 27.4, 29.2, 29.3, 111.9, 112.5, 120.1, 122.7, 124.4, 135.2, 138.4, 142.3, 144.3, 
152.2, 156.6, 158.7, 171.0. MS [ESI, m/z]: 373 [M+Na]. Anal. Calcd for C17H14N6OS: C, 58.27; H, 4.03; 
N, 23.98. Found: C, 58.41; H, 3.86; N, 24.11. 
 
4.1.2.18 6.4.5.2 N'-(5,6-Dimethylthieno[2,3-d]pyrimidin-4-yl)pyrazine-2-carbohydrazide (28c) 
 27 
Obtained in 35% yield as a white solid. M.p. 194-197 °C. 1H-NMR (DMSO-d6), : 2.44 (s, 3H), 2.53 (s, 
3H), 8.31 (s, 1H), 8.81-8.81-8.82 (m, 1H), 8.94 (d, J= 2.3 Hz, 1H), 8.96(broad s, 1H), 9.22 (d, J= 1.2 Hz, 
1H), 10.90 (bs 1H). 13C-NMR (DMSO-d6), : 13.1, 14.0, 116.5, 124.6, 127.1, 129.7, 143.6, 144.4, 146.7, 
147.6, 147.9, 151.8, 161.9. MS [ESI, m/z]: 301 [M+H]. Anal. Calcd for C13H12N6OS: C, 51.99; H, 4.03; 
N, 27.98. Found: C, 51.96; H, 4.11; N, 27.95. 
 
4.1.2.19 2,5-Dihydroxy-N'-(thieno[2,3-d]pyrimidin-4-yl)benzohydrazide (25f) 
Purified by crystallisation from EtOH. Obtained in 15% yield as a light brown solid. M.p. >300 °C. 1H-
NMR (DMSO-d6), : 6.83 (d, J= 8.8 Hz, 1H), 6.93 (dd, J1= 8.8 Hz, J2= 2.8 Hz, 1H), 7.35 (d, J= 2.8 Hz, 
1H), 7.69-7.72 (m, 2H), 8.43 (s, 1H), 9.11 (broad s, 1H), 10.18 (broad s, 1H), 10.73 (bs 1H), 11.07 (broad 
s, 1H).
 
13C-NMR (DMSO-d6), : 113.9, 114.7, 115.3, 117.9, 119.0, 121.6, 124.1, 128.5, 149.4, 149.6, 
151.2, 153.4, 167.2. MS [ESI, m/z]: 303 [M+H]. Anal. Calcd for C13H10N4O3S: C, 51.65; H, 3.33; N, 
18.53. Found: C, 51.57; H, 3.27; N, 18.57. 
 
4.1.2.20 2-Hydroxy-N'-(thieno[2,3-d]pyrimidin-4-yl)benzohydrazide (26f) 
Purified by crystallisation from EtOH. Obtained in 19% yield as a white solid. M.p. 180-183 °C. 1H-
NMR (DMSO-d6), : 6.96-7.01 (m, 2H), 7.46-7.50 (m, 1H), 7.68-7.74 (m, 2H), 7.97 (dd, J1= 7.9 Hz, J2= 
1.0 Hz, 1H), 8.44 (s, 1H), 10.18 (broad s, 1H), 10.85 (broad s 1H), 11.85 (broad s, 1H).
 
13C-NMR 
(DMSO-d6), : 114.7, 117.3, 118.9, 119.0, 120.6, 128.3, 134.1, 134.4, 153.4, 159.1, 167.9. MS [ESI, 
m/z]: 287 [M+H]. Anal. Calcd for C13H10N4OS: C, 54.54; H, 3.52; N, 19.57. Found: C, 54.49; H, 3.33; 
N, 19.61. 
 
4.1.2.21 N'-(Thieno[2,3-d]pyrimidin-4-yl)pyrazine-2-carbohydrazide (28f) 
Purified by crystallisation from EtOH. Obtained in 34% yield a white solid. M.p. 193-197 °C. 1H-NMR 
(DMSO-d6), : 7.68-7.72 (m, 2H), 8.41 (s, 1H), 8.83 (dd, J1= 2.5 Hz, J2= 1.5 Hz, 1H), 8.96 (d, J= 2.5 Hz, 
1H), 9.23 (d, J= 1.5 Hz, 1H), 10.14 (broad s, 1H), 11.06 (bs 1H).
 
13C-NMR (DMSO-d6), : 114.8, 119.0, 
124.0, 123.1, 138.4, 143.6, 143.7, 144.1, 148.1, 153.4, 162.6. MS [ESI, m/z]: 273 [M+H]. Anal. Calcd 
for C11H8N6OS: C, 48.52; H, 2.96; N, 30.86. Found: C, 48.46; H, 2.99; N, 30.95. 
 
4.1.2.22 N'-(Thieno[2,3-d]pyrimidin-4-yl)picolinohydrazide (29f) 
Purified by crystallisation from EtOH. Obtained in 30% yield as a white solid. M.p. 191-194 °C. 1H-
NMR (DMSO-d6), : 7.67-7.71 (m, 3H), 8.03-8.09 (m, 2H), 8.40 (s, 1H), 8.74 (d, J= 4.6 Hz, 1H), 10.09 
(broad s, 1H), 10.87 (bs 1H).
 
13C-NMR (DMSO-d6), : 114.7, 119.1, 121.1, 122.4, 123.9, 127.0, 137.8, 
138.0, 148.7, 149.2, 153.4, 163.5. MS [ESI, m/z]: 272 [M+H]. Anal. Calcd for C12H9N5OS: C, 53.13; H, 
3.34; N, 25.81. Found: C, 53.22; H, 3.31; N, 25.89. 
 
4.1.2.23 N'-(Benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-2,5-dihydroxybenzohydrazide (25g) 
Purified by flash column chromatography eluting with n-hexane-EtOAc 100:0 v/v increasing to n-
hexane-EtOAc 30:70 v/v. Obtained in 17% yield as a light grey solid. TLC (EtOAc, Rf: 0.65). M.p. 241-
244 °C. 1H-NMR (DMSO-d6), : 6.84 (d, J= 8.8 Hz, 1H), 6.93 (dd, J1= 8.8 Hz, J2= 2.8 Hz, 1H), 7.41 (d, 
 28 
J= 2.8 Hz, 1H), 7.58-7.66 (m, 2H), 8.16 (d, J= 7.6 Hz, 1H), 8.56-8.61 (m, 2H), 9.11 (broad s, 1H), 9.64 
(broad s, 1H), 10.92 (broad s, 2H). 13C-NMR (DMSO-d6), : 110.0, 113.9, 115.4, 117.9, 121.6, 123.3, 
124.5, 125.6, 126.7, 130.7, 134.5, 149.6, 151.5, 154.8, 167.1. MS [ESI, m/z]: 353 [M+H]. Anal. Calcd 
for C17H12N4O3S: C, 57.95; H, 3.43; N, 15.90. Found: C, 57.80; H, 3.31; N, 15.92. 
 
4.1.2.24 N'-(Benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-2-hydroxybenzohydrazide (26g) 
Purified by crystallization from EtOH. Obtained in 14% yield as a pale yellow solid. M.p. >300 °C. 
1H-NMR (DMSO-d6), : 6.98-7.03 (m, 2H), 7.48-7.52 (m, 1H), 7.59-7.67 (m, 2H), 8.04 (d, J= 7.5 Hz, 
1H), 8.18 (d, J= 7.3 Hz, 1H), 8.59-8.63 (m, 2H), 9.65 (broad s, 1H), 11.00 (broad s, 1H), 12.00 (broad s, 
1H).
 
13C-NMR (DMSO-d6), : 110.0, 114.7, 117.4, 119.0, 123.3, 124.5, 125.6, 126.7, 128.3, 130.5, 134.1, 
134.5, 154.9, 157.4, 159.3, 167.9. MS [ESI, m/z]: 337 [M+H]. Anal. Calcd for C17H12N4O2S: C, 60.70; 
H, 3.60; N, 16.66. Found: C, 60.63; H, 3.51; N, 16.78. 
 
4.1.2.25 N'-(Benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)pyrazine-2-carbohydrazide (28g) 
Purified by crystallization from EtOH/H2O. Obtained in 21% yield as a pale yellow solid. M.p. 115-118 
°C. 1H-NMR (DMSO-d6), : 7.57-7.65 (m, 2H), 8.15 (d, J= 7.6 Hz, 1H), 8.56 (s, 1H), 8.63 (d, J= 7.3 Hz, 
1H), 8.84-8.85 (m, 1H), 8.96 (d, J= 2.3 Hz, 1H), 9.26 (d, J= 1.3 Hz, 1H), 9.64 (broad s, 1H), 11.14 (broad 
s, 1H). 13C-NMR (DMSO-d6), : 110.1, 123.2, 124.5, 125.6, 125.9, 126.6, 130.7, 134.4, 143.6, 143.7, 
144.0, 144.3, 148.0, 167.8. MS [ESI, m/z]: 323 [M+H]. Anal. Calcd for C15H10N6OS: C, 55.89; H, 3.13; 
N, 26.07. Found: C, 55.80; H, 2.97; N, 26.20. 
 
4.1.2.26 N'-(Benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)picolinohydrazide (29g) 
Purified by crystallization from EtOH. Obtained in 28% yield as a white solid. M.p. 220-223 °C. 1H-
NMR (DMSO-d6), : 7.57-7.65 (m, 2H), 7.68-7.71 (m, 1H), 8.04-8.08 (m, 1H), 8.09-8.12 (m, 1H), 8.15 
(d, J= 7.6 Hz, 1H), 8.56 (s, 1H), 8.63 (d, J= 6.6 Hz, 1H), 8.76 (d, J= 4.3 Hz, 1H), 9.57 (broad s, 1H), 
10.92 (broad s, 1H).
 
13C-NMR (DMSO-d6), : 110.0, 122.3, 123.2, 125.5, 126.6, 126.7, 126.9, 130.7, 
134.4, 137.8, 148.7, 149.3, 154.8, 157.5, 163.2, 167.7. MS [ESI, m/z]: 322 [M+H]. Anal. Calcd for 
C16H11N5OS: C, 59.80; H, 3.45; N, 21.79. Found: C, 59.83; H, 3.49; N, 21.92. 
 
4.1.2.27 2-Hydroxy-N'-(2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl) 
benzohydrazide (26h) 
Purified by crystallisation from MeOH/H2O. Obtained in 36% yield as a light orange solid. M.p. 209-
212 °C. 1H-NMR (DMSO-d6), : 1.82-1.87 (m, 4H), 2.42 (s, 3H), 2.77-2.81 (m, 2H), 2.99-3.03 (m, 2H), 
6.95-7.02 (m, 2H), 7.44-7.48 (m, 1H), 7.98 (d, J= 7.0 Hz, 1H), 8.69 (broad s, 1H), 10.92 (broad s, 1H), 
11.89 (bs 1H). 13C-NMR (DMSO-d6), : 21.9, 22.1, 24.8, 25.4, 25.6, 112.8, 115.2, 117.2, 119.0, 126.1, 
128.4, 131.6, 133.8, 156.3, 158.8, 161.0, 166.1, 166.8. MS [ESI, m/z]: 355 [M+H]. Anal. Calcd for 
C18H18N4O2S: C, 61.00; H, 5.12; N, 15.81. Found: C, 61.11; H, 5.06; N, 15.90. 
 
4.1.2.28 N'-(2-Methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)picolino hydrazide 
(29h) 
 29 
Purified by crystallisation from MeOH/H2O. Obtained in 38% yield as a pale yellow solid. M.p. 99-101 
°C. 1H-NMR (DMSO-d6), : 1.83-1.86 (m, 4H), 2.38 (s, 3H), 2.78-2.81 (m, 2H), 2.98-3.02 (m, 2H), 7.65-
7.69 (m, 1H), 8.02-8.08 (m, 2H), 8.58 (broad s, 1H), 8.72-8.74 (m, 1H), 10.63 (broad s, 1H). 13C-NMR 
(DMSO-d6), : 22.0, 22.2, 24.8, 25.4, 25.6, 112.9, 122.2, 126.2, 126.9, 131.3, 137.8, 148.7, 149.3, 156.6, 
161.0, 162.7, 166.0. MS [ESI, m/z]:  340 [M+H]. Anal. Calcd for C17H17N5OS: C, 60.16; H, 5.05; N, 
20.63. Found: C, 60.11; H, 20.61; N, 5.12. 
 
4.1.2.29 N'-(6-Chloro-5-methylthieno[2,3-d]pyrimidin-4-yl)-2-hydroxybenzohydrazide (26i) 
Purified by crystallisation from MeOH. Obtained in 19% yield as a light grey solid. M.p. 322-324 °C. 
1H-NMR (DMSO-d6), : 2.62 (s, 3H), 6.96-7.00 (m, 2H), 7.45-7.50 (m, 1H), 8.00 (d, J= 7.7 Hz, 1H), 
8.45 (s, 1H), 9.17 (broad s, 1H), 10.87 (broad s, 1H), 11.93 (bs 1H).
 
13C-NMR (DMSO-d6), : 14.1, 
114.7, 114.8, 117.3, 119.0, 123.7, 126.8, 128.4, 134.0, 153.4, 159.0, 168.1. MS [ESI, m/z]: 334.9, 336.9 
[M+H]. Anal. Calcd for C14H11ClN4O2S: C, 50.23; H, 3.31; N, 16.73. Found: C, 50.12; H, 3.57; N, 16.36. 
 
4.1.2.30 N'-(6-Chloro-5-methylthieno[2,3-d]pyrimidin-4-yl)picolinohydrazide (29i) 
Purified by crystallisation from MeOH. Obtained in 61% yield as a pale yellow solid. M.p. 210-212 °C. 
1H-NMR (DMSO-d6), : 2.60 (s, 3H), 7.66-7.69 (m, 1H), 8.03-8.09 (m, 2H), 8.37 (s, 1H), 8.72-8.74 (m, 
1H), 9.26 (broad s, 1H), 10.77 (broad s, 1H).
 
13C-NMR (DMSO-d6), : 14.2, 115.0, 121.4, 122.3, 126.9, 
131.9, 137.8, 144.2, 148.6, 149.3, 162.7. MS [ESI, m/z]: 319.9, 321.9 [M+H]. Anal. Calcd for 
C13H10ClN5OS: C, 48.83; H, 3.15; N, 21.90. Found: C, 48.79; H, 3.12; N, 21.97. 
 
4.1.3 Synthesis of 2-Pyridine sulfonyl acid N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-hydrazide (37) 
Hydrazine 8a (0.20 g, 0.9 mmol) was suspended in pyridine (7 mL) under N2 atmosphere. 2-
Pyridinesulfonyl chloride [46] (0.7 mmol) dissolved in pyridine (3 mL) was then added dropwise to the 
reaction mixture under ice-cooling. The reaction was stirred at 0 °C for 1 h and then at r.t. for 24 h. The 
reaction mixture was then diluted with EtOAc (40 mL) and washed with 0.5 M HCl solution (2 x 50 
mL). The water phase was then extracted with EtOAc (2 x 50 mL) and the organic layers were collected, 
dried over MgSO4 and concentrated under vacuum. The crude residue was purified by crystallisation 
from EtOH giving a white solid in 34% yield. M.p. 189-191 °C. 1H-NMR (DMSO-d6), : 1.78-1.84 (m, 
4H), 2.75-2.79 (m, 2H), 2.90-2.94 (m, 2H), 7.59-7.62 (m, 1H), 7.90 (d, J= 7.7 Hz, 1H), 7.94-8.00 (m, 
1H), 8.02 (s, 1H), 8.63-8.67 (m, 1H), 8.83 (broad s, 1H), 10.10 (broad s, 1H). 13C-NMR (DMSO-d6), : 
21.8, 22.0, 24.9, 25.2, 115.4, 122.7, 126.3, 127.2, 133.3, 138.2, 149.6, 151.4, 156.3, 156.8, 165.2. MS 
[ESI, m/z]: 362 [M+H]. Anal. Calcd for C15H15N5O2S2: C, 49.84; H, 4.18; N, 19.38. Found: C, 49.81; H, 
4.11; N, 19.45. 
 
4.1.4 General method for the preparation of N-aryl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-
d]pyrimidin-4-amines 38-40 
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Hydrazine 8a (0.20 g, 0.9 mmol), the different arylamine (1.8 mmol) and NaHCO3 (0.15 g, 1.8 mmol) 
were heated under reflux in iPrOH (8 mL) for 96 h. The reaction mixture was then cooled to r.t. and 
concentrated under vacuum. The crude residue was purified by flash column chromatography. 
 
4.1.4.1 N-(1H-Benzo[d]imidazol-2-yl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine 
(38)  
Purified by flash column chromatography eluting with n-hexane-EtOAc-MeOH 50:50:0 v/v increasing 
to n-hexane-EtOAc:MeOH 0:95:5 v/v. Obtained in 12% yield as a pale yellow solid. TLC (9:1 EtOAc-
MeOH, Rf: 0.65). M.p. 122-125 °C. 1H-NMR (CDCl3), : 1.52-1.60 (m, 1H), 1.61-1.68 (m, 1H), 1.76-
1.84 (m, 1H), 1.86-1.93 (m, 1H), 2.01-2.09 (m, 1H),
 
2.28-2.34 (m, 1H), 2.89-2.93 (m, 2H), 5.54 (broad 
s, 2H), 6.79 (d, J= 7.9 Hz, 1H), 6.99-7.02 (m, 1H), 7.16-7.19 (m, 1H), 7.46 (d, J= 7.9 Hz, 1H), 9.01 (s, 
1H). 13C-NMR (CDCl3), : 21.9, 22.4, 24.3, 26.1, 108.8, 116.8, 120.6, 122.8, 126.7, 127.1, 134.9, 141.0, 
142.0, 148.0, 152.4, 153.2, 171.7. MS [ESI, m/z]: 322 [M+H]. Anal. Calcd for C17H15N5S: C, 63.53; H, 
4.70; N, 21.79. Found: C, 63.48; H, 4.50; N, 21.81. 
 
4.1.4.2 N-(Quinolin-8-yl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine (39) 
Purified by flash column chromatography eluting with n-hexane-EtOAc 100:0 v/v increasing to n-
hexane-EtOAc 85:15 v/v. Obtained in 14% yield as a pale yellow solid. TLC (7:3 n-hexane-EtOAc, Rf: 
0.59). M.p. 193-196 °C. 1H-NMR (CDCl3), : 1.95-1.99 (m, 2H), 2.03-2.08 (m, 2H), 2.86-2.90 (m, 2H), 
3.32-3.37 (m, 2H), 7.40-7.44 (m, 2H), 7.55-7.59 (m, 1H), 8.14 (d, J= 7.8 Hz, 1H), 8.61 (s, 1H), 8.78-
8.81 (m, 1H), 9.16 (d, J= 7.5 Hz, 1H), 10.24 (broad s, 1H). 13C-NMR (CDCl3), : 22.5, 22.8, 25.6, 26.5, 
116.2, 117.9, 119.9, 121.3, 125.8, 127.4, 128.0, 134.1, 135.7, 136.2, 138.9, 147.8, 152.4, 154.4, 166.0. 
MS [ESI, m/z]: 333 [M+H]. Anal. Calcd for C19H16N4S: C, 68.65; H, 4.85; N, 16.85. Found: C, 4.61; H, 
4.73; N, 16.91. 
 
4.1.2.3 N-(Naphthalen-1-yl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine (40) 
Purified by flash column chromatography eluting with n-hexane-EtOAc 100:0 v/v increasing to n-
hexane-EtOAc 70:30 v/v. Obtained in 21% yield as a pale yellow solid. M.p. 169-172 °C. TLC (7:3 n-
hexane -EtOAc, Rf: 0.46). 1H-NMR (CDCl3), : 1.97-2.02 (m, 2H), 2.03-2.08 (m, 2H), 2.91-2.94 (m, 
2H),
 
3.20-3.23 (m, 2H), 7.38 (broad s, 1H), 7.52-7.56 (m, 2H), 7.57-7.59 (m, 1H), 7.79 (d, J= 8.1 Hz, 
1H7.91-7.95 (m, 2H), 7.99 (d, J= 7.4 Hz, 1H), 8.43 (s, 1H). 13C-NMR (CDCl3), : 22.5, 22.6, 25.6, 26.8, 
116.7, 121.3, 122.2, 125.0, 125.8, 126.1, 126.1, 126.4, 128.7, 128.8, 133.4, 134.4, 134.6, 152.9, 156.3, 
166.5. MS [ESI, m/z]: 332 [M+H]. Anal. Calcd for C20H17N3S: C, 72.48; H, 5.17; N, 12.68. Found: C, 
72.40; H, 5.16; N, 12.73. 
 
4.2 Molecular Modelling 
All molecular modelling studies were performed on a MAC pro 2.66 GHz Quad-Core Intel Xeon, running 
Ubuntu. Molecular Operating Environment (MOE) 2014.10 [28] and Maestro (Schrodinger version 9.0) 
[29] were used as molecular modelling softwares. All minimisations were performed with MOE until 
RMSD gradient of 0.001 Kcal mol-1 Å-1 with the AMBER99 force field. Partial charges were 
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automatically calculated. Conformational analyses were performed with MOE 2014.10; conformers with 
a strain energy >4 kcal/mol were discarded, and the maximum number of conformations per ligand was 
set to 500. In every step MOE default settings were applied. Pharmacophoric filters were created within 
MOE 2010.10 choosing the PCH (polar-charged-hydrophobic) scheme. Docking experiments were 
carried out using GlideSP module in Maestro [29] with the default options. A 12 Å docking grid was 
generated using as centroid defined by Arg393, Glu493 and Trp501 in the 3KQH crystal structure. 
Docking results were rescored using Plants ChemPLP [31], FlexX [32] and Glide XP [30] scoring 
functions. 
 
4.3 HCV replicon assay 
The compounds were dissolved in dimethyl sulfoxide, stored at -20 °C protected from light and further 
diluted in culture medium prior to use. The Huh 5-2 HCV subgenomic replicon-containing cells were 
provided by Prof. R. Bartenschlager (University of Heidelberg, Heidelberg, Germany). Huh 5.2 cells, 
containing the hepatitis C virus genotype 1b I389luc-ubi-neo/NS3-3’/5.1 replicon were sub-cultured in 
DMEM supplemented with 10% FCS, 1% non-essential amino acids, 1% penicillin/streptomycin and 
2% Geneticin at a ratio of 1:3 to 1:4, and grown for 3-4 days in 75 cm2 tissue culture flasks. One day 
before addition of the compound, cells were harvested and seeded in assay medium (DMEM, 10% FCS, 
1% non-essential amino acids, 1% penicillin/streptomycin) at a density of 6 500 cells/well (100 μL/well) 
in 96-well tissue culture microtiter plates for evaluation of anti-metabolic effect and CulturPlate (Perkin 
Elmer) for evaluation of the antiviral effect. The microtiter plates were incubated overnight (37 °C, 5% 
CO2, 95-99% relative humidity), yielding a nonconfluent cell monolayer. The evaluation of the anti-
metabolic as well as antiviral effect of each compound was performed in parallel. 
Four-step, 1-to-5 compound dilution series were prepared for the first screen, to collect data for a more 
detailed dose-response curve, an eight-step, 1-to-2 dilution series was used. Following assay setup, the 
microtiter plates were incubated for 72 hours (37 °C, 5% CO2, 95-99% relative humidity). For the 
evaluation of anti-metabolic effects, the assay medium was aspirated, replaced with 75 μL of a 5% MTS 
solution in phenol red-free medium and incubated for 1.5 hours (37 °C, 5% CO2, 95-99% relative 
humidity). Absorbance was measured at a wavelength of 498 nm (Safire2, Tecan), and optical densities 
(OD values) were converted to percentage of untreated controls. For the evaluation of antiviral effects, 
assay medium was aspirated and the cell monolayers were washed with PBS. The wash buffer was 
aspirated, and 25 μL of Glo Lysis Buffer (Promega) was added allowing for cell lysis to proceed for 5 
min at room temperature. Subsequently, 50 μL of Luciferase Assay System (Promega) was added, and 
the luciferase luminescence signal was quantified immediately (1000 ms integration time/well, Safire, 
Tecan). Relative luminescence units were converted into percentage of untreated controls. 
The EC50 and EC90 (values calculated from the dose-response curve) represent the concentrations at 
which 50% and 90% inhibition, respectively, of viral replication is achieved. The CC50 (value calculated 
from the dose-response curve) represents the concentration at which the metabolic activity of the cells is 
reduced by 50% as compared to untreated cells. 
 
4.4 HCV NS3 helicase enzymatic assays 
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Molecular beacon-based NS3 helicase assays were performed as described by Hanson et al. [47] 
Reactions contained 25mM MOPS pH 6.5, 1.25mM MgCl2, 5% DMSO, 5 µg/ml BSA, 0.01% (v/v) 
Tween20, 0.05 mM DTT, 5 nM florescent DNA substrate, 12.5 nM NS3h, and 1 mM ATP.  The ability 
of each compound to displace NS3 from a DNA oligonucleotide was monitored as described by 
Mukherjee et al. [48].  Each assay contained 15 nM NS3h, 25 mM MOPS, pH 7.5, 1.25 mM MgCl2, 
0.0025 mg/ml BSA, 0.005% (v/v) Tween20, 0.025 mM DTT and 12.5nM NS3h_(1b). The ability of NS3 
to hydrolyze ATP was monitored as described by Sweeney et al. [49].  Reactions performed in the 
presence of RNA contained 25mM MOPS pH 6.5, 1.25mM MgCl2, 15 µM Poly U RNA (Sigma), 6 nM 
NS3h_1b(con1) in 5 μg/mL BSA, 0.001% Tween 20. Reactions performed in the absence of RNA 
contained all the same reagents except that 300 nM NS3h _1b(con1) was included. To determine the 
compound concentration needed to reduce helicase catalyzed ATP hydrolysis by 50 % (IC50), reactions 
were performed in duplicate two-fold dilution series such that final compound concentrations ranged 
from 0.5 mM to 0.78 µM. Data obtained from all reactions within the linear range of the assays were 
normalized to controls lacking inhibitor (100%) and controls lacking enzyme (0%), and fit to a 
normalized dose response equation with a variable Hill slope using GraphPad Prism (v. 6). Reactions 
were performed in duplicate and each titration was fit to the above concentration response equation. 
Average IC50 values ± standard deviations are reported. 
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